RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3

Abstract

The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application Ser. No. 60/917,392, filed May 11, 2007, and U.S. Provisional Application Ser. No. 61/023,250, filed Jan. 24, 2008, the disclosures of which are incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

[0002] The invention relates to oligomeric compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3. Reduction of HER3 expression is beneficial for a range medical disorders, such as hyperproliferative diseases, including cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 using said oligomers, including methods of treatment.

BACKGROUND

[0003] HER3 belongs to the ErbB family of receptor tyrosine kinases, which includes four different receptors: ErbB-1 (EGFR, HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4) (Yarden et al, Nat. Rev. Mol. Cell. Biol, 2001, 2(2):127-137). The receptor proteins of this family are composed of an extracellular ligand-binding domain, a hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase-containing domain. Growth factors of the EGF family bind to most of the ErbB receptors and activate them. HER3 (ErbB3) is characterized by a lack of tyrosine kinase activity. EGFR, HER2 and recently HER3 have been associated with tumour formation. Recent studies, for example, have shown that EGFR is over expressed in a number of malignant human tissues when compared to their normal tissue counterparts. A high incidence of over expression, amplification, deletion and structural rearrangement of the gene coding for the EGFR has been found in biopsies of brain tumours. Amplification of the EGFR gene in glioblastoma multiforme tumours is one of the most consistent genetic alterations known. Elevated levels of HER3 mRNA have been detected in human mammary carcinomas. Recently, it has been shown that inhibition of Her2 and EGFR tyrosine kinase activity using tyrosine kinase inhibitors show limited effect on HER2-driven breast cancers due to a compensatory increase in HER3 expression and subsequent signalling through the PI3K/Akt pathway (Sergina et al., Nature, 2007, 445:437-441).

[0004] U.S. Pat. No. 6,277,640 to Bennett et al. discloses antisense compounds, compositions and methods for inhibiting the expression of HER3.

[0005] There is a need for agents capable of effectively inhibiting HER3 function.

SUMMARY OF INVENTION

[0006] The invention provides an oligomer of 10-50 monomers, such as 10-30 monomers, which comprises a first region of between 10-50 monomers, or 10-30 monomers, wherein the sequence of said first region is at least 80% identical to the reverse complement of a target region of a mammalian HER3 gene or mRNA, such as SEQ ID NO: 197, or a naturally occurring variant thereof.

[0007] The invention provides oligomer of 10-50 monomers which comprises a first region of 10-50 monomers, wherein the sequence of said first region is at least 80% identical to a sequence of an oligomer as shown in SEQ ID NOs:200-226 or 227.

[0008] The invention provides an oligomer of 10-50 monomers which comprises a first region of 10-50 monomers, wherein said the sequence of said first region is at least 80% identical to a sequence of an oligomer as shown in SEQ ID NOS:1-140, 228-232 or 233.

[0009] The invention further provides a conjugate comprising an oligomer according to the invention, which is covalently attached to one or more moieties that are not themselves nucleic acids or monomers ("conjugated moiety"). The conjugated moiety may comprise a sterol group such as cholesterol, or other chemical moiety that facilitates entry into the cell.

[0010] The invention provides for a conjugate comprising the oligomer according to the invention, which is covalently linked to a polymeric conjugated moiety containing positively charged groups, such as polyethylene glycol (PEG)--i.e. the oligomer according to the invention may, optionally, be pegylated.

[0011] The invention provides for a pharmaceutical composition comprising an oligomer of the invention or a conjugate thereof, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

[0012] The invention provides for use of an oligomer of the invention or conjugate thereof as a medicament for the treatment of one or more of diseases, such as a hyperproliferative disease, such as cancer.

[0013] The invention further provides for an oligomer according to the invention for use in medicine.

[0014] The invention provides for the use of an oligomer of the invention or a conjugate thereof, for the preparation or manufacture of a medicament for the treatment of hyperproliferative diseases, such as cancer.

[0015] The invention provides for a method of treating hyperproliferative diseases such as cancer, said method comprising administering to a patient in need thereof an effective amount of an oligomer of the invention, or a conjugate or a pharmaceutical composition according to the invention.

[0016] The invention provides for a method of inhibiting (e.g., by down-regulating) the expression of HER3 in a cell which is expressing HER3, said method comprising administering an effective amount of an oligomer according to the invention, or a conjugate thereof, to said cell so as to effect the inhibition of HER3 expression in said cell.

[0017] Further provided are methods of inhibiting (e.g., by down-regulating) the expression of HER3, and/or EGFR and/or HER2, in cells or tissues comprising contacting said cells or tissues, in vitro or in vivo, with an effective amount of one or more oligomers of the invention, or conjugates or compositions thereof, to effect down-regulation of the expression of HER3 and/or EGFR and/or HER2.

[0018] Also disclosed are methods of treating a non-human animal or a human suspected of having, or being prone to, a disease or condition associated with expression, or over-expression, of HER3 (and/or EGFR and/or HER2), comprising administering to said non-human animal or human a therapeutically or prophylactically effective amount of one or more of oligomers of the invention, or conjugates or compositions thereof.

[0019] Methods of using one or more oligomers of the invention for the inhibition of expression of HER3 and/or EGFR and/or HER2, and for treating diseases associated with activity of HER3 (and/or EGFR and/or HER2) are also provided.

[0020] The invention provides for a method of triggering apoptosis in a cell or tissue, such as a cancer cell, said method comprising the step of contacting said cell or tissue with an effective amount of oligomer of the invention, or a conjugate, or a pharmaceutical composition thereof so that expression of HER3, and/or EGFR and/or HER2, is inhibited or reduced and apoptosis is triggered.

[0021] The invention further provides for an oligomer which comprises or consists of a first region, wherein the sequence of said first region is at least 80% identical to the sequence of a region of an oligomer having a sequence selected from the group consisting of SEQ ID NOs: 1-140, 200-232 and 233, such as a sequence selected from the group consisting of SEQ ID NOs: 200, 211, 54 and 1.

[0022] The invention further provides for an oligomer which comprises or consists of a first region, the sequence of said first region being identically present in an oligomer having a sequence selected from the group consisting of SEQ ID NO 169-196 and 234, such as SEQ ID NO: 169 or SEQ ID NO: 180.

[0023] The invention further provides for an oligomer which has a sequence selected from the group consisting of SEQ ID NOs: 169-196 and 234, such as the sequence of SEQ ID NO: 169 or 180, or which comprises or consists of a first region, the sequence of said first region being identically present in an oligomer selected from the group consisting of SEQ ID NOs: 169-196 and 234.

BRIEF DESCRIPTION OF THE FIGURES

[0024] FIG. 1. The HER3 target sequences that are targeted by the oligomers having the sequence of SEQ ID NOS: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, and 140, respectively, are shown in bold and underlined, indicating their position in the HER3 transcript (GenBank Accession number NM_--001982--SEQ ID NO:197).

[0025] FIG. 2. HER3 mRNA expression in 15PC3, 24 hours after transfection, SEQ ID NOS:169-179

[0026] FIG. 3. EGFR mRNA expression in 15PC3, 24 hours after transfection, SEQ ID NOS:169-179

[0027] FIG. 4. HER-2 mRNA expression in 15PC3, 24 hours after transfection, SEQ ID NOS:169-179

[0028] FIG. 5: HER3 mRNA expression in 15PC3, 24 hours after transfection, SEQ ID NOS: 180-194

[0029] FIG. 6: Data show apoptosis induction measured as activated Caspase 3/7 at different time points in HUH7 cells transfected with oligonucleotides at 5 and 25 nM concentrations. Results are plotted relative to cells mock treated with a scrambled control oligonucleotide having SEQ ID NO: 235.

[0030] FIG. 7: Data show viable cells measured as OD490 using MTS assay at different time points in HUH-7 cells transfected with oligonucleotides at 5 and 25 nM concentrations. SEQ ID NO: 235 is a scrambled control oligonucleotide.

[0031] FIG. 8A: Data show percent change in tumour volume in 15PC3 xenograft tumours transplanted onto female nude mice treated with SEQ ID NO: 180 i.v. at 25 and 50 mg/kg q3dx10. Saline treated mice were used as control.

[0032] FIG. 8B: Data show HER3 mRNA expression in 15PC3 xenograft tumours transplanted onto female nude mice treated with SEQ ID NO: 180 i.v. at 25 and 50 mg/kg q3dx10. Results are normalised to GAPDH and presented as % of saline treated controls.

[0033] FIG. 9: Data show HER3 mRNA expression in mouse liver after treatment i.v. with 1 or 5 mg/kg oligonucleotides on three consecutive days having sequences shown in SEQ ID NO: 180 or SEQ ID NO: 234. Results are normalised to GAPDH and presented as % of saline treated controls.

DETAILED DESCRIPTION

[0034] In some embodiments, the invention provides sequences, compositions and methods for modulating the expression of HER3 (and/or EGFR and/or HER2). In particular, this invention relates to target sequences in the HER3 gene, the sequence information of which in some embodiments is used to generate complementary antisense oligonucleotides capable of down-regulating the expression of HER3. In various embodiments, the invention further provides oligonucleotides (oligomers) which specifically hybridise under intracellular conditions to nucleic acids encoding HER3, and their uses to treat or prevent diseases associated with HER3 over-expression, e.g., cancer. In some embodiments, oligonucleotides of the invention down-regulate the expression of HER3. In other embodiments, oligonucleotides of the invention down-regulate the expression of HER3, HER2 and/or EGFR.

[0035] The term "HER3" is used herein interchangeably with the term "ErbB3".

The Oligomer

[0036] In a first aspect, oligomeric compounds (referred to herein as oligomers), are provided that are useful, e.g., in modulating the function of nucleic acid molecules encoding mammalian HER3, such as the HER3 nucleic acid shown in SEQ ID No: 197, and naturally occurring allelic variants of such nucleic acid molecules encoding mammalian HER3. The oligomers of the invention are composed of covalently linked monomers.

[0037] The term "monomer" includes both nucleosides and deoxynucleosides (collectively, "nucleosides") that occur naturally in nucleic acids and that do not contain either modified sugars or modified nucleobases, i.e., compounds in which a ribose sugar or deoxyribose sugar is covalently bonded to a naturally-occurring, unmodified nucleobase (base) moiety (i.e., the purine and pyrimidine heterocycles adenine, guanine, cytosine, thymine or uracil) and "nucleoside analogues," which are nucleosides that either do occur naturally in nucleic acids or do not occur naturally in nucleic acids, wherein either the sugar moiety is other than a ribose or a deoxyribose sugar (such as bicyclic sugars or 2' modified sugars, such as 2' substituted sugars), or the base moiety is modified (e.g., 5-methylcytosine), or both.

[0038] An "RNA monomer" is a nucleoside containing a ribose sugar and an unmodified nucleobase.

[0039] A "DNA monomer" is a nucleoside containing a deoxyribose sugar and an unmodified nucleobase.

[0040] A "Locked Nucleic Acid monomer," "locked monomer," or "LNA monomer" is a nucleoside analogue having a bicyclic sugar, as further described herein below.

[0041] The terms "corresponding nucleoside analogue" and "corresponding nucleoside" indicate that the base moiety in the nucleoside analogue and the base moiety in the nucleoside are identical. For example, when the "nucleoside" contains a 2-deoxyribose sugar linked to an adenine, the "corresponding nucleoside analogue" contains, for example, a modified sugar linked to an adenine base moiety.

[0042] The terms "oligomer," "oligomeric compound," and "oligonucleotide" are used interchangeably in the context of the invention, and refer to a molecule formed by covalent linkage of two or more contiguous monomers by, for example, a phosphate group (forming a phosphodiester linkage between nucleosides) or a phosphorothioate group (forming a phosphorothioate linkage between nucleosides). The oligomer consists of, or comprises, 10-50 monomers, such as 10-30 monomers.

[0043] In some embodiments, an oligomer comprises nucleosides, or nucleoside analogues, or mixtures thereof as referred to herein. An "LNA oligomer" or "LNA oligonucleotide" refers to an oligonucleotide containing one or more LNA monomers.

[0044] Nucleoside analogues that are optionally included within oligomers may function similarly to corresponding nucleosides, or may have specific improved functions. Oligomers wherein some or all of the monomers are nucleoside analogues are often preferred over native forms because of several desirable properties of such oligomers, such as the ability to penetrate a cell membrane, good resistance to extra- and/or intracellular nucleases and high affinity and specificity for the nucleic acid target. LNA monomers are particularly preferred, for example, for conferring several of the above-mentioned properties.

[0045] In various embodiments, one or more nucleoside analogues present within the oligomer are "silent" or "equivalent" in function to the corresponding natural nucleoside, i.e., have no functional effect on the way the oligomer functions to inhibit target gene expression. Such "equivalent" nucleoside analogues are nevertheless useful if, for example, they are easier or cheaper to manufacture, or are more stable under storage or manufacturing conditions, or can incorporate a tag or label. Typically, however, the analogues will have a functional effect on the way in which the oligomer functions to inhibit expression; for example, by producing increased binding affinity to the target region of the target nucleic acid and/or increased resistance to intracellular nucleases and/or increased ease of transport into the cell.

[0046] Thus, in various embodiments, oligomers according to the invention comprise nucleoside monomers and at least one nucleoside analogue monomer, such as an LNA monomer, or other nucleoside analogue monomers.

[0047] The term "at least one" comprises the integers larger than or equal to 1, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 and so forth. In various embodiments, such as when referring to the nucleic acid or protein targets of the compounds of the invention, the term "at least one" includes the terms "at least two" and "at least three" and "at least four." Likewise, in some embodiments, the term "at least two" comprises the terms "at least three" and "at least four."

[0048] In some embodiments, the oligomer consists of 10-50 contiguous monomers, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous monomers.

[0049] In some embodiments, the oligomer consists of 10-25 monomers, preferably, 10-16 monomers, and more preferably, 12-16 monomers.

[0050] In various embodiments, the oligomers comprise or consist of 10-25 contiguous monomers, 10-24 contiguous monomers, 12-25 or 12-24 or 10-22 contiguous monomers, such as 12-18 contiguous monomers, such as 13-17 or 12-16 contiguous monomers, such as 13, 14, 15, 16 contiguous monomers.

[0051] In various embodiments, the oligomers comprise or consist of 10-22 contiguous monomers, or 10-18, such as 12-18 or 13-17 or 12-16, such as 13, 14, 15 or 16 contiguous monomers.

[0052] In some embodiments, the oligomers comprise or consist of 10-16 or 12-16 or 12-14 contiguous monomers. In other embodiments, the oligomers comprise or consist of 14-18 or 14-16 contiguous monomers.

[0053] In various embodiments, the oligomers comprise or consist of 10, 11, 12, 13, or 14 contiguous monomers.

[0054] In various embodiments, the oligomer according to the invention consists of no more than 22 contiguous monomers, such as no more than 20 contiguous monomers, such as no more than 18 contiguous monomers, such as 15, 16 or 17 contiguous monomers. In certain embodiments, the oligomer of the invention comprises less than 20 contiguous monomers.

[0055] In various embodiments, the oligomer of the invention does not comprise RNA monomers.

[0056] It is preferred that the oligomers according to the invention are linear molecules or are linear as synthesized. The oligomer is, in such embodiments, a single stranded molecule, and typically does not comprise a short region of, for example, at least 3, 4 or 5 contiguous monomers, which are complementary to another region within the same oligomer such that the oligomer forms an internal duplex. In various embodiments, the oligomer is not substantially double-stranded, i.e., is not a siRNA.

[0057] In some embodiments, the oligomer of the invention consists of a contiguous stretch of monomers, the sequence of which is identified by a SEQ ID NO. disclosed herein (see, e.g., Tables 1-4). In other embodiments, the oligomer comprises a first region, the region consisting of a contiguous stretch of monomers, and one or more additional regions which consist of at least one additional monomer. In some embodiments, the sequence of the first region is identified by a SEQ ID NO. disclosed herein.

Gapmer Design

[0058] Typically, the oligomer of the invention is a gapmer.

[0059] A "gapmer" is an oligomer which comprises a contiguous stretch of monomers capable of recruiting an RNAse (e.g. RNAseH) as further described herein below, such as a region of at least 6 or 7 DNA monomers, referred to herein as region B, wherein region B is flanked both on its 5' and 3' ends by regions respectively referred to as regions A and C, each of regions A and C comprising or consisting of nucleoside analogues, such as affinity-enhancing nucleoside analogues, such as 1-6 nucleoside analogues.

[0060] Typically, the gapmer comprises regions, from 5' to 3', A-B-C, or optionally A-B-C-D or D-A-B-C, wherein: region A consists of or comprises at least one nucleoside analogue, such as at least one LNA monomer, such as 1-6 nucleoside analogues, such as LNA monomers; and region B consists of or comprises at least five contiguous monomers which are capable of recruiting RNAse (when formed in a duplex with a complementary target region of the target RNA molecule, such as the mRNA target), such as DNA monomers; and region C consists of or comprises at least one nucleoside analogue, such as at least one LNA monomer, such as 1-6 nucleoside analogues, such as LNA monomers, and; region D, when present, consists of or comprises 1, 2 or 3 monomers, such as DNA monomers.

[0061] In various embodiments, region A consists of 1, 2, 3, 4, 5 or 6 nucleoside analogues, such as LNA monomers, such as 2-5 nucleoside analogues, such as 2-5 LNA monomers, such as 3 or 4 nucleoside analogues, such as 3 or 4 LNA monomers; and/or region C consists of 1, 2, 3, 4, 5 or 6 nucleoside analogues, such as LNA monomers, such as 2-5 nucleoside analogues, such as 2-5 LNA monomers, such as 3 or 4 nucleoside analogues, such as 3 or 4 LNA monomers.

[0062] In certain embodiments, region B consists of or comprises 5, 6, 7, 8, 9, 10, 11 or 12 contiguous monomers which are capable of recruiting RNAse, or 6-10, or 7-9, such as 8 contiguous monomers which are capable of recruiting RNAse. In certain embodiments, region B consists of or comprises at least one DNA monomer, such as 1-12 DNA monomers, preferably 4-12 DNA monomers, more preferably 6-10 DNA monomers, such as 7-10 DNA monomers, most preferably 8, 9 or 10 DNA monomers.

[0063] In certain embodiments, region A consists of 3 or 4 nucleoside analogues, such as LNA monomers, region B consists of 7, 8, 9 or 10 DNA monomers, and region C consists of 3 or 4 nucleoside analogues, such as LNA monomers. Such designs include (A-B-C) 3-10-3, 3-10-4, 4-10-3, 3-9-3, 3-9-4, 4-9-3, 3-8-3, 3-8-4, 4-8-3, 3-7-3, 3-7-4, 4-7-3, and may further include region D, which may have one or 2 monomers, such as DNA monomers.

[0064] Further gapmer designs are disclosed in WO 2004/046160, which is hereby incorporated by reference.

[0065] U.S. provisional application, 60/977,409, hereby incorporated by reference, refers to "shortener" gapmer oligomers. In some embodiments, oligomers presented here may be such shortener gapmers.

[0066] In certain embodiments, the oligomer consists of 10, 11, 12, 13 or 14 contiguous monomers, wherein the regions of the oligomer have the pattern (5'-3'), A-B-C, or optionally A-B-C-D or D-A-B-C, wherein; region A consists of 1, 2 or 3 nucleoside analogue monomers, such as LNA monomers; region B consists of 7, 8 or 9 contiguous monomers which are capable of recruiting RNAse when formed in a duplex with a complementary RNA molecule (such as a mRNA target); and region C consists of 1, 2 or 3 nucleoside analogue monomers, such as LNA monomers. When present, region D consists of a single DNA monomer.

[0067] In certain embodiments, region A consists of 1 LNA monomer. In certain embodiments, region A consists of 2 LNA monomers. In certain embodiments, region A consists of 3 LNA monomers. In certain embodiments, region C consists of 1 LNA monomer. In certain embodiments, region C consists of 2 LNA monomers. In certain embodiments, region C consists of 3 LNA monomers. In certain embodiments, region B consists of 7 nucleoside monomers. In certain embodiments, region B consists of 8 nucleoside monomers. In certain embodiments, region B consists of 9 nucleoside monomers. In certain embodiments, region B comprises 1-9 DNA monomers, such as 2, 3, 4, 5, 6, 7 or 8 DNA monomers. In certain embodiments, region B consists of DNA monomers. In certain embodiments, region B comprises at least one LNA monomer which is in the alpha-L configuration, such as 2, 3, 4, 5, 6, 7, 8 or 9 LNA monomers in the alpha-L-configuration. In certain embodiments, region B comprises at least one alpha-L-oxy LNA monomer. In certain embodiments, all the LNA monomers in region B that are in the alpha-L-configuration are alpha-L-oxy LNA monomers. In certain embodiments, the number of monomers present in the A-B-C regions of the oligomers is selected from the group consisting of (nucleotide analogue monomers--region B--nucleoside analogue monomers): 1-8-1, 1-8-2, 2-8-1, 2-8-2, 3-8-3, 2-8-3, 3-8-2, 4-8-1, 4-8-2, 1-8-4, 2-8-4, or; 1-9-1, 1-9-2, 2-9-1, 2-9-2, 2-9-3, 3-9-2, 1-9-3, 3-9-1, 4-9-1, 1-9-4, or; 1-10-1, 1-10-2, 2-10-1, 2-10-2, 1-10-3, and 3-10-1. In certain embodiments, the number of monomers present in the A-B-C regions of the oligomers of the invention is selected from the group consisting of: 2-7-1, 1-7-2, 2-7-2, 3-7-3, 2-7-3, 3-7-2, 3-7-4, and 4-7-3. In certain embodiments, each of regions A and C consists of two LNA monomers, and region B consists of 8 or 9 nucleoside monomers, preferably DNA monomers.

[0068] In various embodiments, other gapmer designs include those where regions A and/or C consists of 3, 4, 5 or 6 nucleoside analogues, such as monomers containing a 2'-O-methoxyethyl-ribose sugar (2'MOE) or monomers containing a 2'-fluoro-deoxyribose sugar, and region B consists of 8, 9, 10, 11 or 12 nucleosides, such as DNA monomers, where regions A-B-C have 5-10-5 or 4-12-4 monomers. Further gapmer designs are disclosed in WO 2007/146511A2, hereby incorporated by reference.

Linkage Groups

[0069] The monomers of the oligomers described herein are coupled together via linkage groups. Suitably, each monomer is linked to the 3' adjacent monomer via a linkage group.

[0070] The terms "linkage group" or "internucleoside linkage" mean a group capable of covalently coupling together two contiguous monomers. Specific and preferred examples include phosphate groups (forming a phosphodiester between adjacent nucleoside monomers) and phosphorothioate groups (forming a phosphorothioate linkage between adjacent nucleoside monomers).

[0071] Suitable linkage groups include those listed in WO 2007/031091, for example the linkage groups listed on the first paragraph of page 34 of WO 2007/031091 (hereby incorporated by reference).

[0072] It is, in various embodiments, preferred to modify the linkage group from its normal phosphodiester to one that is more resistant to nuclease attack, such as phosphorothioate or boranophosphate--these two, being cleavable by RNase H, permitting RNase-mediated antisense inhibition of expression of the target gene.

[0073] In some embodiments, suitable sulphur (S) containing linkage groups as provided herein are preferred. In various embodiments, phosphorothioate linkage groups are preferred, particularly for the gap region (B) of gapmers. In certain embodiments, phosphorothioate linkages are used to link together monomers in the flanking regions (A and C). In various embodiments, phosphorothioate linkages are used for linking regions A or C to region D, and for linking together monomers within region D.

[0074] In various embodiments, regions A, B and C comprise linkage groups other than phosphorothioate, such as phosphodiester linkages, particularly, for instance when the use of nucleoside analogues protects the linkage groups within regions A and C from endo-nuclease degradation--such as when regions A and C comprise LNA monomers.

[0075] In various embodiments, adjacent monomers of the oligomer are linked to each other by means of phosphorothioate groups.

[0076] It is recognised that the inclusion of phosphodiester linkages, such as one or two linkages, into an oligomer with a phosphorothioate backbone, particularly with phosphorothioate linkage groups between or adjacent to nucleoside analogue monomers (typically in region A and/or C), can modify the bioavailability and/or bio-distribution of an oligomer--see WO 2008/053314, hereby incorporated by reference.

[0077] In some embodiments, such as the embodiments referred to above, where suitable and not specifically indicated, all remaining linkage groups are either phosphodiester or phosphorothioate, or a mixture thereof.

[0078] In some embodiments all the internucleoside linkage groups are phosphorothioate.

[0079] When referring to specific gapmer oligonucleotide sequences, such as those provided herein, it will be understood that, in various embodiments, when the linkages are phosphorothioate linkages, alternative linkages, such as those disclosed herein, may be used, for example phosphate (phosphodiester) linkages may be used, particularly for linkages between nucleoside analogues, such as LNA monomers.

Target Nucleic Acid

[0080] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein, and are defined as a molecule formed by covalent linkage of two or more monomers, as above-described. Including 2 or more monomers, "nucleic acids" may be of any length, and the term is generic to "oligomers", which have the lengths described herein. The terms "nucleic acid" and "polynucleotide" include single-stranded, double-stranded, partially double-stranded, and circular molecules.

[0081] In various embodiments, the term "target nucleic acid", as used herein, refers to the nucleic acid (such as DNA or RNA) encoding mammalian HER3 polypeptide (e.g., such as human HER3 mRNA having the sequence in SEQ ID NO 197, or mammalian mRNAs having GenBank Accession numbers NM_--001005915, NM_--001982 and alternatively-spliced forms NP_--001973.2 and NP_--001005915.1 (human); NM_--017218 (rat); NM_--010153 (mouse); NM_--001103105 (cow); or predicted mRNA sequences having GenBank Accession numbers XM_--001491896 (horse), XM_--001169469 and XM_--509131 (chimpanzee)).

[0082] In various embodiments, "target nucleic acid" also includes a nucleic acid encoding a mammalian HER2 polypeptide (e.g., such mammalian mRNAs having GenBank Accession numbers NM_--001005862 and NM_--004448 (human); NM_--017003 and NM_--017218 (rat); NM_--001003817 (mouse); NM_--001003217 (dog); and NM_--001048163 (cat)).

[0083] In various embodiments, "target nucleic acid" also includes a nucleic acid encoding a mammalian EGFR polypeptide (e.g., such as mammalian mRNAs having GenBank Accession numbers NM_--201284, NM_--201283, NM_--201282 and

[0084] NM_--005228 (human); NM_--007912 and NM_--207655 (mouse); NM_--031507 (rat); and NM_--214007 (pig)).

[0085] It is recognized that the above-disclosed GenBank Accession numbers refer to cDNA sequences and not to mRNA sequences per se. The sequence of a mature mRNA can be derived directly from the corresponding cDNA sequence, with thymine bases (T) being replaced by uracil bases (U).

[0086] In various embodiments, "target nucleic acid" also includes HER3 (or HER2 or EGFR) encoding nucleic acids or naturally occurring variants thereof, and RNA nucleic acids derived therefrom, preferably mRNA, such as pre-mRNA, although preferably mature mRNA. In various embodiments, for example when used in research or diagnostics the "target nucleic acid" is a cDNA or a synthetic oligonucleotide derived from the above DNA or RNA target nucleic acids. The oligomers according to the invention are typically capable of hybridising to the target nucleic acid.

[0087] The term "naturally occurring variant thereof" refers to variants of the HER3 (or HER2 or EGFR) polypeptide or nucleic acid sequence which exist naturally within the defined taxonomic group, such as mammalian, such as mouse, monkey, and preferably human. Typically, when referring to "naturally occurring variants" of a polynucleotide the term also may encompass any allelic variant of the HER3 (or HER2 or EGFR) encoding genomic DNA which is found at the Chromosome Chr 12: 54.76-54.78 Mb by chromosomal translocation or duplication, and the RNA, such as mRNA derived therefrom. When referenced to a specific polypeptide sequence, e.g., the term also includes naturally occurring forms of the protein which may therefore be processed, e.g. by co- or post-translational modifications, such as signal peptide cleavage, proteolytic cleavage, glycosylation, etc.

[0088] In certain embodiments, oligomers described herein bind to a region of the target nucleic acid (the "target region") by either Watson-Crick base pairing, Hoogsteen hydrogen bonding, or reversed Hoogsteen hydrogen bonding, between the monomers of the oligomer and monomers of the target nucleic acid. Such binding is also referred to as "hybridisation." Unless otherwise indicated, binding is by Watson-Crick pairing of complementary bases (i.e., adenine with thymine (DNA) or uracil (RNA), and guanine with cytosine), and the oligomer binds to the target region because the sequence of the oligomer is identical to, or partially-identical to, the sequence of the reverse complement of the target region; for purposes herein, the oligomer is said to be "complementary" or "partially complementary" to the target region, and the percentage of "complementarity" of the oligomer sequence to that of the target region is the percentage "identity" to the reverse complement of the sequence of the target region.

[0089] Unless otherwise made clear by context, the "target region" herein will be the region of the target nucleic acid having the sequence that best aligns with the reverse complement of the sequence of the specified oligomer (or region thereof), using the alignment program and parameters described herein below.

[0090] In determining the degree of "complementarity" between oligomers of the invention (or regions thereof) and the target region of the nucleic acid which encodes mammalian HER3 (or HER2 or EGFR), such as those disclosed herein, the degree of "complementarity" (also, "homology") is expressed as the percentage identity between the sequence of the oligomer (or region thereof) and the reverse complement of the sequence of the target region that best aligns therewith. The percentage is calculated by counting the number of aligned bases that are identical as between the 2 sequences, dividing by the total number of contiguous monomers in the oligomer, and multiplying by 100. In such a comparison, if gaps exist, it is preferable that such gaps are merely mismatches rather than areas where the number of monomers within the gap differs between the oligomer of the invention and the target region.

[0091] Amino acid and polynucleotide alignments, percentage sequence identity, and degree of complementarity may be determined for purposes of the invention using the ClustalW algorithm using standard settings: see http://www.ebi.ac.uk/emboss/align/index.html, Method: EMBOSS::water (local): Gap Open=10.0, Gap extend=0.5, using Blosum 62 (protein), or DNAfull for nucleotide/nucleobase sequences.

[0092] As will be understood, depending on context, "mismatch" refers to a nonidentity in sequence (as, for example, between the nucleobase sequence of an oligomer and the reverse complement of the target region to which it binds; as for example, between the base sequence of two aligned HER3 encoding nucleic acids), or to noncomplementarity in sequence (as, for example, between an oligomer and the target region to which binds).

[0093] Suitably, the oligomer (or conjugate, as further described, below) is capable of inhibiting (such as, by down-regulating) expression of the HER3 (or HER2 or EGFR) gene.

[0094] In various embodiments, the oligomers of the invention effect inhibition of HER3 (or HER2 or EGFR) mRNA expression of at least 10% as compared to the normal expression level, at least 20%, more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% as compared to the normal expression level. In various embodiments, the oligomers of the invention effect inhibition of HER3 (or HER2 or EGFR) protein expression of at least 10% as compared to the normal expression level, at least 20%, more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% as compared to the normal expression level. In some embodiments, such inhibition is seen when using 1 nM of the oligomer or conjugate of the invention. In various embodiments, such inhibition is seen when using 25 nM of the oligomer or conjugate.

[0095] In various embodiments, the inhibition of mRNA expression is less than 100% (i.e., less than complete inhibition of expression), such as less than 98%, inhibition, less than 95% inhibition, less than 90% inhibition, less than 80% inhibition, such as less than 70% inhibition. In various embodiments, the inhibition of protein expression is less than 100% (i.e., less than complete inhibition of expression), such as less than 98%, inhibition, less than 95% inhibition, less than 90% inhibition, less than 80% inhibition, such as less than 70% inhibition.

[0096] Alternatively, modulation of expression levels can be determined by measuring levels of mRNA, e.g. by northern blotting or quantitative RT-PCR. When measuring via mRNA levels, the level of inhibition when using an appropriate dosage, such as 1 and 25 nM, is, in various embodiments, typically to a level of 10-20% of the normal levels in the absence of the compound of the invention.

[0097] Modulation (i.e., inhibition or increase) of expression level may also be determined by measuring protein levels, e.g. by methods such as SDS-PAGE followed by western blotting using suitable antibodies raised against the target protein.

[0098] In some embodiments, the invention provides oligomers that inhibit (e.g., down-regulate) the expression of one or more alternatively-spliced isoforms of HER3 mRNA and/or proteins derived therefrom. In some embodiments, the invention provides oligomers that inhibit expression of one or more of the alternatively-spliced protein isoforms of HER3 (GenBank Accession nos. NP_--001973.2 and NP_--001005915.1) and/or expression of the nucleic acids that encode the HER3 protein isoforms (GenBank Accession nos. NM_--001982 and NM_--001005915.1). In some embodiments, the mRNA encoding HER3 isoform 1 is the target nucleic acid. In other embodiments, the mRNA encoding HER3 isoform 2 is the target nucleic acid. In certain embodiments, the nucleic acids encoding HER3 isoform 1 and HER3 isoform 2 are target nucleic acids, for example, the oligomer having the sequence of SEQ ID NO: 180.

[0099] In various embodiments, the invention provides oligomers, or a first region thereof, having a base sequence that is complementary to the sequence of a target region in a HER3 nucleic acid, which oligomers down-regulate HER3 mRNA and/or HER3 protein expression and down-regulate the expression of mRNA and/or protein of one or more other ErbB receptor tyrosine kinase family members, such as HER2 and/or EGFR. Oligomers, or a first region thereof, that effectively bind to the target regions of two different ErbB receptor family nucleic acids (e.g., HER2 and HER3 mRNA) and that down-regulating the mRNA and/or protein expression of both targets are termed "bispecific." Oligomers, or a first region thereof, that bind to the target regions of three different ErbB receptor family members and are capable of effectively down-regulating all three genes are termed "trispecific". In various embodiments, an antisense oligonucleotide of the invention may be polyspecific, i.e. capable of binding to target regions of target nucleic acids of multiple members of the ErbB family of receptor tyrosine kinases and down-regulating their expression. As used herein, the terms "bispecific" and "trispecific" are understood not to be limiting in any way. For example, a "bispecific oligomer" may have some effect on a third target nucleic acid, while a "trispecific oligomer" may have a very weak and therefore insignificant effect on one of its three target nucleic acids.

[0100] In various embodiments, bispecific oligomers, or a first region thereof, are capable of binding to a target region in a HER3 nucleic acid and a target region in a HER2 target nucleic acid and effectively down-regulating the expression of HER3 and HER2 mRNA and/or protein. In certain embodiments, the bispecific oligomers do not down-regulate expression of HER3 mRNA and/or protein and HER2 mRNA and/or protein to the same extent. In other preferred embodiments, the bispecific oligomers of the invention, or a first region thereof, are capable of binding to a target region in a HER3 target nucleic acid and a target region in an EGFR target nucleic acid and effectively down-regulating the expression of HER3 mRNA and/or protein and EGFR mRNA and/or protein. In various embodiments, the bispecific oligomers do not down-regulate expression of HER3 mRNA and/or protein and EGFR mRNA and/or protein to the same extent. In still other embodiments, trispecific oligomers, or a first region thereof, are capable of binding to a target region in a HER3 target nucleic acid, and to target regions in two other ErbB family of receptor tyrosine kinase target nucleic acids and effectively down-regulating the expression of HER3 mRNA and/or protein and mRNA and/or protein of the two other members of the ErbB family of receptor tyrosine kinases. In various preferred embodiments, the trispecific oligomers, or a first region thereof, are capable of effectively down-regulating the expression of HER3 mRNA and/or protein, the expression of HER2 mRNA and/or protein, and the expression of EGFR mRNA and/or protein. In various embodiments, the trispecific oligomers do not down-regulate expression of HER3 mRNA and/or protein, HER2 mRNA and/or protein and EGFR mRNA and/or protein to the same extent.

[0101] In various embodiments, the invention therefore provides a method of inhibiting (e.g., by down-regulating) the expression of HER3 protein and/or mRNA in a cell which is expressing HER3 protein and/or mRNA, the method comprising contacting the cell with an amount of an oligomer or conjugate according to the invention effective to inhibit (e.g., to down-regulate) the expression of HER3 protein and/or mRNA in said cell. Suitably the cell is a mammalian cell, such as a human cell. The contacting may occur, in certain embodiments, in vitro. In other embodiments, the contacting may be effected in vivo, by administering the compound or conjugate of the invention to a mammal. In various embodiments, the invention provides a method of inhibiting (e.g., by down-regulating) the expression of HER3 protein and/or mRNA and the expression of HER2 protein and/or mRNA in a cell. The sequence of the human HER2 mRNA is shown in SEQ ID NO: 199. In still further embodiments, the invention provides a method of inhibiting (e.g., by down-regulating) the expression of HER3 protein and/or mRNA and the expression of EGFR protein and/or mRNA in a cell. The sequence of the human EGFR mRNA is shown in SEQ ID NO: 198. In yet further embodiments, the invention provides a method of inhibiting (e.g., by down-regulating) the expression of HER3, HER2 and EGFR mRNA and/or protein in a cell.

[0102] An oligomer of the invention typically binds to a target region of the human HER3 and/or the human HER2 and/or the human EGFR mRNA, and as such, comprises or consists of a region having a base sequence that is complementary or partially complementary to the base sequence of, e.g., SEQ ID NO 197, SEQ ID NO: 198 and/or SEQ ID NO: 199. In certain embodiments, the sequence of the oligomers of the invention may optionally comprise 1, 2, 3, 4 or more base mismatches when compared to the sequence of the best-aligned target region of SEQ ID NOs: 197, 198 or 199.

[0103] In some embodiments, the oligomers of the invention have sequences that are identical to a sequence selected from the group consisting of SEQ ID NOs: 200-227, 1-140 and 228-233 (see Table 1 herein below). In other embodiments, the oligomers of the invention have sequences that differ in one, two, or three bases when compared to a sequence selected from the group consisting of SEQ ID NOs: 200-227, 1-140 and 228-233. In some embodiments, the oligomers consist of or comprise 10-16 contiguous monomers. Examples of the sequences of oligomers consisting of 16 contiguous monomers are SEQ ID NOs: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, and 140. Shorter sequences can be derived therefrom, e.g., the sequence of the shorter oligomer may be identically present in a region of an oligomer selected from those having base sequences of SEQ ID NOs: 200-227, 1-140 and 228-233. Longer oligomers may include a region having a sequence of at least 10 contiguous monomers that is identically present in SEQ ID NOs: 200-227, 1-140 and 228-233.

[0104] Further provided are target nucleic acids (e.g., DNA or mRNA encoding HER3), that contain target regions that are complementary or partially-complementary to one or more of the oligomers of SEQ ID NOs: 1-140, wherein the oligomers are capable of inhibiting expression (e.g., by down-regulation) of HER3 protein or mRNA. For example, target regions of human HER3 mRNA which are complementary to the antisense oligomers having sequences of SEQ ID NOs: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, and 140 are shown in FIG. 1 (bold and underlined, with the corresponding oligomer SEQ ID NOs indicated above).

[0105] In various embodiments, the oligomers have the base sequences shown in SEQ ID NOs: 141-168. In certain embodiments, the oligomers are LNA oligomers, for example, those having the sequences of SEQ ID NOS: 169-196 and 234, in particular those having the base sequences of SEQ ID NOs: 169, 170, 173, 174, 180, 181, 183, 185, 187, 188, 189, 190, 191, 192 and 194. In various embodiments, the oligomers are LNA oligomers such as those having base sequences of SEQ ID NOs: 169, 170, 172, 174, 175, 176 and 179. In some embodiments, the oligomers or a region thereof consist of or comprise a base sequence as shown in SEQ ID NOs: 169, 180 or 234. In some embodiments, conjugates of the invention include an oligomer having a base sequence as shown in SEQ ID NOs: 169, 180 or 234.

[0106] In certain embodiments, the oligomer of the invention may, suitably, comprise a region having a particular sequence, such as a sequence selected from SEQ ID NOs: 200-227, that is identically present in a shorter oligomer of the invention. Preferably, the region comprises 10-16 monomers. For example, the oligomers having the base sequences of SEQ ID NOs: 200-227 each comprise a region wherein the sequence of the region is identically present in shorter oligomers having sequences of SEQ ID NOs: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, and 140, respectively. In some embodiments, oligomers which have fewer than 16 monomers, such as 10, 11, 12, 13, 14, or 15 monomers, have a region of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14 or 15, contiguous monomers of which the sequence is identically present in oligomers having sequences of SEQ ID NOS: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, or 140. Hence, in various embodiments, the sequences of shorter oligomers are derived from the sequences of longer oligomers. In some embodiments, the sequences of oligomers having SEQ ID NOs disclosed herein, or the sequences of at least 10 contiguous monomers thereof, are identically present in longer oligomers. Typically an oligomer of the invention comprises a first region having a sequence that is identically present in SEQ ID NOs: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, or 140, and if the oligomer is longer than the first region that is identically present in SEQ ID NOs: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139, or 140, the flanking regions of the oligomer have sequences that are complementary to the sequences flanking the target region of the target nucleic acid. Two such oligomers are SEQ ID NO: 1 and SEQ ID NO: 54.

[0107] In various embodiments, the oligomer comprises or consists of a sequence of monomers which is fully complementary (perfectly complementary) to a target region of a target nucleic acid which encodes a mammalian HER3.

[0108] However, in some embodiments, the sequence of the oligomer includes 1, 2, 3, or 4 (or more) mismatches as compared to the best-aligned target region of a HER3 target nucleic acid, and still sufficiently binds to the target region to effect inhibition of HER3 mRNA or protein expression. The destabilizing effect of mismatches on the Watson-Crick hydrogen-bonded duplex may, for example, be compensated by increased length of the oligomer and/or an increased number of nucleoside analogues, such as LNA monomers, present within the oligomer.

[0109] In various embodiments, the oligomer base sequence comprises no more than 3, such as no more than 2 mismatches compared to the base sequence of the best-aligned target region of, for example, a target nucleic acid which encodes a mammalian HER3.

[0110] The base sequences of the oligomers of the invention or of a region thereof are preferably at least 80% identical to a sequence selected from the group consisting of SEQ ID NOS: 200-227, 1-140 and 228-233, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, even 100% identical.

[0111] The base sequences of the oligomers of the invention or of a first region thereof are preferably at least 80% complementary to a sequence of a target region present in SEQ ID NOs: 197, 198 and/or 199 such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, even 100% complementary.

[0112] In various embodiments, the sequence of the oligomer (or a first region thereof) is selected from the group consisting of SEQ ID NOs: 200-227, 1-140 and 228-233, or is selected from the group consisting of at least 10 contiguous monomers of SEQ ID NOs: 200-227, 1-140 and 228-233. In other embodiments, the sequence of the oligomer of the invention or a first region thereof optionally comprises 1, 2 or 3 base moieties that differ from those in oligomers having sequences of SEQ ID NOs: 200-227, 1-140 and 228-233, or the sequences of at least 10 contiguous monomers thereof, when optimally aligned with said selected sequence or region thereof.

[0113] In certain embodiments, the monomer region consists of 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 contiguous monomers, such as between 10-15, 12-25, 12-22, such as between 12-18 monomers. Suitably, in various embodiments, the region is of the same length as the oligomer of the invention.

[0114] In some embodiments, the oligomer comprises additional monomers at the 5' or 3' ends, such as, independently, 1, 2, 3, 4 or 5 additional monomers 5' end and/or 3' end of the oligomer, which are non-complementary to the sequence of the target region. In various embodiments, the oligomer of the invention comprises a region that is complementary to the target, which is flanked 5' and/or 3' by additional monomers. In various embodiments, the 3' end of the region is flanked by 1, 2 or 3 DNA or RNA monomers. 3' DNA monomers are frequently used during solid state synthesis of oligomers. In various embodiments, which may be the same or different, the 5' end of the oligomer is flanked by 1, 2 or 3 DNA or RNA monomers. In certain embodiments, the additional 5' or 3' monomers are nucleosides, such as DNA or RNA monomers. In various embodiments, the 5' or 3' monomers may represent region D as referred to in the context of gapmer oligomers herein.

[0115] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:200, or according to a region thereof.

[0116] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:201, or according to a region thereof.

[0117] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:202, or according to a region thereof.

[0118] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:203, or according to a region thereof.

[0119] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:204, or according to a region thereof.

[0120] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:205, or according to a region thereof.

[0121] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:206, or according to a region thereof.

[0122] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:207, or according to a region thereof.

[0123] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:208, or according to a region thereof.

[0124] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:209, or according to a region thereof.

[0125] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:210, or according to a region thereof.

[0126] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:211, or according to a region thereof.

[0127] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:212, or according to a region thereof.

[0128] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:213, or according to a region thereof.

[0129] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:214, or according to a region thereof.

[0130] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:215, or according to a region thereof.

[0131] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:216, or according to a region thereof.

[0132] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:217, or according to a region thereof.

[0133] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:218, or according to a region thereof.

[0134] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:219, or according to a region thereof.

[0135] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:220, or according to a region thereof.

[0136] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:221, or according to a region thereof.

[0137] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:222, or according to a region thereof.

[0138] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:223, or according to a region thereof.

[0139] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:224, or according to a region thereof.

[0140] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:225, or according to a region thereof.

[0141] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:226, or according to a region thereof.

[0142] In certain embodiments, the oligomer according to the invention consists of, or comprises, contiguous monomers having a nucleobase sequence according to SEQ ID NO:227, or according to a region thereof.

[0143] Sequence alignments (such as those described above) can be used to identify regions of the nucleic acids encoding HER3 (or HER2 or EGFR) from human and one or more different mammalian species, such as monkey, mouse and/or rat, where there are sufficient stretches of nucleic acid identity between or among the species to allow the design of oligonucleotides which target (that is, which bind with sufficient specificity to inhibit expression of) both the human HER3 (or HER2 or EGFR) target nucleic acid and the corresponding nucleic acids present in the different mammalian species.

[0144] In some embodiments, such oligomers consist of or comprise regions of at least 10, such as at least 12, such as at least 14, such as at least 16, such as at least 18, such as 11, 12, 13, 14, 15, 16, 17 or 18 contiguous monomers which are 100% complementary in sequence to the sequence of the target regions of the nucleic acid encoding HER3 (or HER2 or EGFR) from humans and of the nucleic acid(s) encoding HER3 (or HER2 or EGFR) from a different mammalian species.

[0145] In some embodiments, the oligomer of the invention comprises or consists of a region of contiguous monomers having a sequence that is at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 98% or 100% complementary to the sequence of the target regions of both the nucleic acid encoding human HER3 (or HER2 or EGFR) and a nucleic acid(s) encoding HER3 (or HER2 or EGFR) from a different mammalian species, such as the mouse nucleic acid encoding HER3 (or HER2 or EGFR). It is preferable that the contiguous nucleobase sequence of the oligomer is 100% complementary to the target region of the human HER3 (or HER2 or EGFR) mRNA.

[0146] In some embodiments, oligomers of the invention bind to a target region of a HER3 target nucleic acid and down-regulate the expression of HER3 mRNA and/or protein. In various embodiments, oligomers of the invention that bind to a target region of a HER3 nucleic acid have the sequences shown, for example, in SEQ ID NOs:169-196 and 234.

[0147] In some embodiments, a first region of a bispecific oligomer of the invention binds to a target region of a HER 3 nucleic acid and a second region of the bispecific oligomer binds to a target region of a HER2 nucleic acid and said oligomer down-regulates the expression of HER3 and HER2. In various embodiments, the bispecific oligomer down-regulates the expression of HER 3 and HER2 to a different extent. In some embodiments, the first region and the second region of the oligomer are the same. In various embodiments, the first region and the second region of the oligomer overlap. In certain embodiments, the bispecific oligomers of the invention that bind to a target region of HER3 nucleic acid and a target region of HER2 nucleic acid have the sequences shown, for example, in SEQ ID NOs:177 and 178. In still other embodiments, a bispecific oligomer of the invention binds to a target region of HER3 nucleic acid and to a target region of EGFR nucleic acid and down-regulates the expression of HER3 and EGFR. In some embodiments, bispecific oligomers of the invention that bind to a target region of HER3 nucleic acid and to a target region of EGFR nucleic acid have the sequences shown, for example, in SEQ ID NOs: 171 and 173. In some embodiments, a first region of a bispecific oligomer of the invention binds to a target region of HER 3 nucleic acid and a second region of the bispecific oligomer binds to a target region of EGFR nucleic acid and said oligomer down-regulates the expression of HER3 and EGFR. In various embodiments, the bispecific oligomer down-regulates the expression of HER 3 and EGFR to a different extent. In some embodiments, the first region and the second region of the oligomer are the same. In various embodiments, the first region and the second region of the oligomer overlap. In yet further embodiments, trispecific oligomers of the invention bind to a target region of HER3 nucleic acid, to a target region of HER2 nucleic acid and to a target region of EGFR nucleic acid and down-regulate the expression of all three genes. In some embodiments, trispecific oligomers of the invention that bind to HER3, HER2 and EGFR have the sequences shown, for example, in SEQ ID NOs:169, 170, 172, 174-176 and 179. In some embodiments, a first region of a trispecific oligomer of the invention binds to a target region of HER 3 nucleic acid, a second region of the trispecific oligomer binds to a target region of EGFR nucleic acid, and a third region of the trispecific oligomer binds to a target region of HER2 nucleic acid, and said oligomers down-regulate the expression of HER3, HER2 and EGFR. In various embodiments, the trispecific oligomer down-regulates the expression of HER 3, HER2 and EGFR to different extents. In some embodiments, the first, second and third regions of the oligomer are the same. In various embodiments, the first, second and third regions of the oligomer overlap. In various embodiments, bispecific or trispecific oligomers have 1, 2, 3, 4, 5 or more mismatches when compared to the best-aligned target regions of, e.g., target nucleic acids having sequences shown in SEQ ID NO: 197, 198 and/or 199.

Nucleosides and Nucleoside Analogues

[0148] In various embodiments, at least one of the monomers present in the oligomer is a nucleoside analogue that contains a modified base, such as a base selected from 5-methylcytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine, 2-chloro-6-aminopurine, xanthine and hypoxanthine.

[0149] In various embodiments, at least one of the monomers present in the oligomer is a nucleoside analogue that contains a modified sugar.

[0150] In some embodiments, the linkage between at least 2 contiguous monomers of the oligomer is other than a phosphodiester linkage.

[0151] In certain embodiments, the oligomer includes at least one monomer that has a modified base, at least one monomer (which may be the same monomer) that has a modified sugar, and at least one inter-monomer linkage that is non-naturally occurring.

[0152] Specific examples of nucleoside analogues useful in the oligomers described herein are described by e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and in Scheme 1 (in which some nucleoside analogues are shown as nucleotides):

##STR00001## ##STR00002##

[0153] The oligomer may thus comprise or consist of a simple sequence of nucleosides--preferably DNA monomers, but also possibly RNA monomers, or a combination of nucleosides and one or more nucleoside analogues. In some embodiments, such nucleoside analogues suitably enhance the affinity of the oligomer for the target region of the target nucleic acid.

[0154] Examples of suitable and preferred nucleoside analogues are described in WO 2007/031091, incorporated herein by reference in its entirety, or are referenced therein.

[0155] In some embodiments, the nucleoside analogue comprises a sugar moiety modified to provide a 2'-substituent group, such as 2'-O-alkyl-ribose sugars, 2'-amino-deoxyribose sugars, and 2'-fluoro-deoxyribose sugars.

[0156] In some embodiments, the nucleoside analogue comprises a sugar in which a bridged structure, creating a bicyclic sugar (LNA), is present, which enhances binding affinity and may also provide some increased nuclease resistance. In various embodiments, the LNA monomer is selected from oxy-LNA (such as beta-D-oxy-LNA, and alpha-L-oxy-LNA), and/or amino-LNA (such as beta-D-amino-LNA and alpha-L-amino-LNA) and/or thio-LNA (such as beta-D-thio-LNA and alpha-L-thio-LNA) and/or ENA (such as beta-D-ENA and alpha-L-ENA). In certain embodiments, the LNA monomers are beta-D-oxy-LNA. LNA monomers are further described below.

[0157] In various embodiments, incorporation of affinity-enhancing nucleoside analogues in the oligomer, such as LNA monomers or monomers containing 2'-substituted sugars, or incorporation of modified linkage groups provides increased nuclease resistance. In various embodiments, incorporation of such affinity-enhancing nucleoside analogues allows the size of the oligomer to be reduced, and also reduce the upper limit to the size of the oligomer before non-specific or aberrant binding takes place.

[0158] In certain embodiments, the oligomer comprises at least 2 nucleoside analogues. In some embodiments, the oligomer comprises from 3-8 nucleoside analogues, e.g. 6 or 7 nucleoside analogues. In preferred embodiments, at least one of the nucleoside analogues is a locked nucleic acid (LNA) monomer; for example at least 3 or at least 4, or at least 5, or at least 6, or at least 7, or 8 nucleoside analogues are LNA monomers. In some embodiments all the nucleosides analogues are LNA monomers.

[0159] It will be recognised that when referring to a preferred oligomer base sequence, in certain embodiments the oligomers comprise a corresponding nucleoside analogue, such as a corresponding LNA monomer or other corresponding nucleoside analogue, which raises the duplex stability (T_m) of the oligomer/target region duplex (i.e. affinity enhancing nucleoside analogues).

[0160] In various preferred embodiments, any mismatches (that is, noncomplementarities) between the base sequence of the oligomer and the base sequence of the target region, if present, are located other than in the regions of the oligomer that contain affinity-enhancing nucleoside analogues (e.g., regions A or C), such as within region B as referred to herein, and/or within region D as referred to herein, and/or in regions which are 5' or 3' to the region of the oligomer that is complementary to the target region.

[0161] In some embodiments the nucleoside analogues present within the oligomer of the invention (such as in regions A and C mentioned herein) are independently selected from, for example: monomers containing 2'-O-alkyl-ribose sugars, monomers containing 2'-amino-deoxyribose sugars, monomers containing 2'-fluoro-deoxyribose sugars, LNA monomers, monomers containing arabinose sugars ("ANA monomers"), monomers containing 2'-fluoro-arabinose sugars, monomers containing d-arabino-hexitol sugars ("HNA monomers"), intercalating monomers as defined in Christensen, Nucl. Acids. Res. 30: 4918-4925 (2002), hereby incorporated by reference, and monomers containing 2'MOE sugars. In certain embodiments, there is only one of the above types of nucleoside analogues present in the oligomer of the invention, or region thereof.

[0162] In certain embodiments, the nucleoside analogues contain 2'-O-methoxyethyl-ribose sugars (2'MOE), or 2'-fluoro-deoxyribose sugars or LNA sugars, and as such the oligonucleotide of the invention may comprise nucleoside analogues which are independently selected from these three types. In certain oligomer embodiments containing nucleoside analogues, at least one of said nucleoside analogues contains a 2'-MOE-ribose sugar, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleoside analogues containing 2'-MOE-ribose sugars. In certain embodiments, at least one of said nucleoside analogues contains a 2'-fluoro-deoxyribose sugar, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleoside analogues containing 2'-fluoro-deoxyribose sugars.

[0163] In various embodiments, the oligomer according to the invention comprises at least one Locked Nucleic Acid (LNA) monomer, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA monomers, such as 3-7 or 4-8 LNA monomers, or 3, 4, 5, 6 or 7 LNA monomers. In various embodiments, all of the nucleoside analogues are LNA monomers. In some embodiments, the oligomer comprises both beta-D-oxy-LNA monomers, and one or more of the following LNA monomers: thio-LNA monomers, amino-LNA monomers, oxy-LNA monomers, and/or ENA monomers in either the beta-D or alpha-L configuration, or combinations thereof. In certain embodiments, the cytosine base moieties of all LNA monomers in the oligomer are 5-methylcytosines. In certain embodiments of the invention, the oligomer comprises both LNA and DNA monomers. Typically, the combined total of LNA and DNA monomers is 10-25, preferably 10-20, even more preferably 12-16. In certain embodiments of the invention, the oligomer or region thereof consists of at least one LNA monomer, and the remaining monomers are DNA monomers. In certain embodiments, the oligomer comprises only LNA monomers and nucleosides (such as RNA or DNA monomers, most preferably DNA monomers) optionally linked with modified linkage groups such as phosphorothioate.

[0164] In various embodiments, at least one of the nucleoside analogues present in the oligomer has a modified base selected from the group consisting of 5-methylcytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, diaminopurine, and 2-chloro-6-aminopurine.

LNA

[0165] The term "LNA monomer" refers to a nucleoside analogue containing a bicyclic sugar (an "LNA sugar"). The terms "LNA oligonucleotide" and "LNA oligomer" refer to an oligomer containing one or more LNA monomers.

[0166] The LNA used in the oligonucleotide compounds of the invention preferably has the structure of the general formula I

##STR00003##

[0167] wherein X is selected from --O--, --S--, --N(R^N*)--, --C(R⁶R⁶*)--;

[0168] B is selected from hydrogen, optionally substituted C₁-4-alkoxy, optionally substituted C₁-4-alkyl, optionally substituted C₁-4-acyloxy, nucleobases, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

[0169] P designates the radical position for an internucleoside linkage to a succeeding monomer, or a 5'-terminal group, such internucleoside linkage or 5'-terminal group optionally including the substituent R⁵ or equally applicable the substituent R⁵*;

[0170] P* designates an internucleoside linkage to a preceding monomer, or a 3'-terminal group;

[0171] R⁴* and R²* together designate a biradical consisting of 1-4 groups/atoms selected from --C(R^aR^b)--, --C(R^a)═C(R^b)--, --C(R^a)═N--, --O--, --Si(R^a)₂--, --S--, N(R^a)--, and >C═Z, [0172] wherein Z is selected from --O--, --S--, and --N(R^a)--, and R^a and R^b each is independently selected from hydrogen, optionally substituted C₁-12-alkyl, optionally substituted C₂-12-alkenyl, optionally substituted C₂-12-alkynyl, hydroxy, C₁-12-alkoxy, C₂-12-alkoxyalkyl, C₂-12-alkenyloxy, carboxy, C₁-12-alkoxycarbonyl, C₁-12-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C₁-6-alkyl)amino, carbamoyl, mono- and di(C₁-6-alkyl)-amino-carbonyl, amino-C₁-6-alkyl-aminocarbonyl, mono- and di(C₁-6-alkyl)amino-C₁-6-alkyl-aminocarbonyl, C₁-6-alkyl-carbonylamino, carbamido, C₁-6-alkanoyloxy, sulphono, C₁-6-alkylsulphonyloxy, nitro, azido, sulphanyl, C₁-6-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted and where two geminal substituents R^a and R^b together may designate optionally substituted methylene (═CH₂), and

[0173] each of the substituents R¹*, R², R³, R⁵, R⁵*, R⁶ and R⁶*, which are present is independently selected from hydrogen, optionally substituted C₁-12-alkyl, optionally substituted C₂-12-alkenyl, optionally substituted C₂-12-alkynyl, hydroxy, C₁-12-alkoxy, C₂-12-alkoxyalkyl, C₂-12-alkenyloxy, carboxy, C₁-12-alkoxycarbonyl, C₁-12-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C₁-6-alkyl)amino, carbamoyl, mono- and di(C₁-6-alkyl)-amino-carbonyl, amino-C₁-6-alkyl-aminocarbonyl, mono- and di(C₁-6-alkyl)amino-C₁-6-alkyl-aminocarbonyl, C₁-6-alkyl-carbonylamino, carbamido, C₁-6-alkanoyloxy, sulphono, C₁-6-alkylsulphonyloxy, nitro, azido, sulphanyl, C₁-6-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted, and where two geminal substituents together may designate oxo, thioxo, imino, or optionally substituted methylene, or together may form a spiro biradical consisting of a 1-5 carbon atom(s) alkylene chain which is optionally interrupted and/or terminated by one or more heteroatoms/groups selected from --O--, --S--, and --(NR^N)--where R^N is selected from hydrogen and C₁-4-alkyl, and where two adjacent (non-geminal) substituents may designate an additional bond resulting in a double bond; and R^N*, when present and not involved in a biradical, is selected from hydrogen and C₁-4-alkyl; and basic salts and acid addition salts thereof;

[0174] In certain embodiments, R⁵* is selected from H, --CH₃, --CH₂--CH₃, --CH₂--O--CH₃, and --CH═CH₂.

[0175] In various embodiments, R⁴* and R²* together designate a biradical selected from --C(R^aR^b)--O--, --C(R^aR^b)--C(R^cR^d)--O--, --C(R^aR^b)--C(R^cR^d)--C(R^eR^f)--O--, --C(R^aR^b)--O--C(R^cR^d)--, --C(R^aR^b)--O--C(R^cR^d)--O--, --C(R^aR^b)--C(R^cR^d)--, --C(R^aR^b)--C(R^cR^d)--C(R^eR^f)--, --C(R^a)═C(R^b)--C(R^cR^d)--, --C(R^aR^b)--N(R^b)--, --C(R^aR^b)--C(R^cR^d)--N(R^e)--, --C(R^aR^b)--N(R^c)--O--, and --C(R^aR^b)--S--, --C(R^aR^b)--C(R^cR^d)--S--, wherein R^a, R^b, R^c, R^d, R^e, and R^f each is independently selected from hydrogen, optionally substituted C₁-12-alkyl, optionally substituted C₂-12-alkenyl, optionally substituted C₂-12-alkynyl, hydroxy, C₁-12-alkoxy, C₂-12-alkoxyalkyl, C₂-12-alkenyloxy, carboxy, C₁-12-alkoxycarbonyl, C₁-12-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C₁-6-alkyl)amino, carbamoyl, mono- and di(C₁-6-alkyl)-amino-carbonyl, amino-C₁-6-alkyl-aminocarbonyl, mono- and di(C₁-6-alkyl)amino-C₁-6-alkyl-aminocarbonyl, C₁-6-alkyl-carbonylamino, carbamido, C₁-6-alkanoyloxy, sulphono, C₁-6-alkylsulphonyloxy, nitro, azido, sulphanyl, C₁-6-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted and where two geminal substituents R^a and R^b together may designate optionally substituted methylene (═CH₂),

[0176] In further embodiments R⁴* and R²* together designate a biradical selected from --CH₂--O--, --CH₂--S--, --CH₂--NH--, --CH₂--N(CH₃)--, --CH₂--CH₂--O--, --CH₂--CH(CH₃)--, CH₂--CH₂--S--, --CH₂--CH₂--NH--, --CH₂--CH₂--CH₂--, --CH₂--CH₂--CH₂--O--, --CH₂--CH₂--CH(CH₃)--, --CH═CH--CH₂--, --CH₂--O--CH₂--O--, --CH₂--NH--O--, --CH₂--N(CH₃)--O--, --CH₂--O--CH₂--, --CH(CH₃)--O--, --CH(CH₂--O--CH₃)--O--.

[0177] For all chiral centers, asymmetric groups may be found in either R or S orientation.

[0178] Preferably, the LNA monomer used in the oligomers of the invention comprises at least one LNA monomer according to any of the formulas

##STR00004##

[0179] wherein Y is --O--, --O--CH₂--, --S--, --NH--, or N(R^H); Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group; B constitutes an unmodified base moiety or a modified base moiety that either occurs naturally in nucleic acids or does not occur naturally in nucleic acids, and R^H is selected from hydrogen and C₁-4-alkyl.

[0180] Specifically preferred LNA monomers are shown in Scheme 2:

##STR00005##

[0181] The term "thio-LNA" refers to an LNA monomer in which Y in the general formula above is selected from S or --CH₂--S--. Thio-LNA can be in either the beta-D or the alpha-L-configuration.

[0182] The term "amino-LNA" refers to an LNA monomer in which Y in the general formula above is selected from --N(H)--, N(R)--, CH₂--N(H)--, and --CH₂--N(R)-- where R is selected from hydrogen and C₁-4-alkyl. Amino-LNA can be in either the beta-D or the alpha-L-configuration.

[0183] The term "oxy-LNA" refers to an LNA monomer in which Y in the general formula above represents --O-- or --CH₂--O--. Oxy-LNA can be in either the beta-D or the alpha-L-configuration.

[0184] The term "ENA" refers to an LNA monomer in which Y in the general formula above is --CH₂--O-- (where the oxygen atom of --CH₂--O-- is attached to the 2'-position relative to the base B).

[0185] In a preferred embodiment the LNA monomer is selected from a beta-D-oxy-LNA monomer, an alpha-L-oxy-LNA monomer, a beta-D-amino-LNA monomer and a beta-D-thio-LNA monomer, in particular a beta-D-oxy-LNA monomer.

[0186] In the present context, the term "C₁-4-alkyl" means a linear or branched saturated hydrocarbon chain wherein the chain has from one to four carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.

RNAse H Recruitment

[0187] In some embodiments, an oligomer functions via non-RNase-mediated degradation of a target mRNA, such as by steric hindrance of translation, or other mechanisms; however, in various embodiments, oligomers of the invention are capable of recruiting an endoribonuclease (RNase), such as RNase H.

[0188] Typically, the oligomer comprises a region of at least 6, such as at least 7 contiguous monomers, such as at least 8 or at least 9 contiguous monomers, including 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 contiguous monomers, which, when forming a duplex with the target region of the target RNA, is capable of recruiting RNase. The region of the oligomer which is capable of recruiting RNAse may be region B, as referred to in the context of a gapmer as described herein. In certain embodiments, the region of the oligomer which is capable of recruiting RNAse, such as region B, consists of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 monomers.

[0189] EP 1 222 309 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability of the oligomers of the invention to recruit RNaseH. An oligomer is deemed capable of recruiting RNase H if, when contacted with the complementary target region of the RNA target, it has an initial rate, as measured in pmol/l/min, of at least 1%, such as at least 5%, such as at least 10% or less than 20% of an oligonucleotide having the same base sequence but containing only DNA monomers, with no 2' substitutions, with phosphorothioate linkage groups between all monomers in the oligonucleotide, using the methodology provided by Example 91-95 of EP 1 222 309, incorporated herein by reference.

[0190] In various embodiments, an oligomer is deemed essentially incapable of recruiting RNaseH if, when contacted with the complementary target region of the RNA target, and RNaseH, the RNaseH initial rate, as measured in pmol/l/min, is less than 1%, such as less than 5%, such as less than 10% or less than 20% of the initial rate determined using an oligonucleotide having the same base sequence, but containing only DNA monomers, with no 2' substitutions, with phosphorothioate linkage groups between all monomers in the oligonucleotide, using the methodology provided by Example 91-95 of EP 1 222 309.

[0191] In other embodiments, an oligomer is deemed capable of recruiting RNaseH if, when contacted with the complementary target region of the RNA target, and RNaseH, the RNaseH initial rate, as measured in pmol/l/min, is at least 20%, such as at least 40%, such as at least 60%, such as at least 80% of the initial rate determined using an oligonucleotide having the same base sequence, but containing only DNA monomers, with no 2' substitutions, with phosphorothioate linkage groups between all monomers in the oligonucleotide, using the methodology provided by Example 91-95 of EP 1 222 309.

[0192] Typically, the region of the oligomer that forms a duplex with the complementary target region of the target RNA and is capable of recruiting RNase contains DNA monomers and LNA monomers and forms a DNA/RNA like duplex with the target region. The LNA monomers are preferably in the alpha-L configuration, particularly preferred being alpha-L-oxy LNA.

[0193] In various embodiments, the oligomer of the invention comprises both nucleosides and nucleoside analogues, and is in the form of a gapmer as defined above, a headmer or a mixmer.

[0194] A "headmer" is defined as an oligomer that comprises a first region and a second region that is contiguous thereto, with the 5'-most monomer of the second region linked to the 3'-most monomer of the first region. The first region comprises a contiguous stretch of non-RNase-recruiting nucleoside analogues, and the second region comprises a contiguous stretch (such as at least 7 contiguous monomers) of DNA monomers or nucleoside analogue monomers recognizable and cleavable by the RNAse.

[0195] A "tailmer" is defined as an oligomer that comprises a first region and a second region that is contiguous thereto, with the 5'-most monomer of the second region linked to the 3'-most monomer of the first region. The first region comprises a contiguous stretch (such as at least 7 such monomers) of DNA monomers or nucleoside analogue monomers recognizable and cleavable by the RNase, and the second region comprises a contiguous stretch of non-RNase recruiting nucleoside analogue monomers.

[0196] Other "chimeric" oligomers, called "mixmers", consist of an alternating composition of (i) DNA monomers or nucleoside analogue monomers recognizable and cleavable by RNase, and (ii) non-RNase recruiting nucleoside analogue monomers.

[0197] In some embodiments, in addition to enhancing affinity of the oligomer for the target region, some nucleoside analogues also mediate RNase (e.g., RNase H) binding and cleavage. Since α-L-LNA monomers recruit RNase activity to a certain extent, in some embodiments, gap regions (e.g., region B as referred to herein below) of oligomers containing α-L-LNA monomers consist of fewer monomers recognizable and cleavable by the RNase, and more flexibility in the mixmer construction is introduced.

[0198] Conjugates

[0199] In the context of this disclosure, the term "conjugate" indicates a compound formed by the covalent attachment ("conjugation") of an oligomer, as described herein, to one or more moieties that are not themselves nucleic acids or monomers ("conjugated moiety"). Examples of such conjugated moieties include macromolecular compounds such as proteins, fatty acid chains, sugar residues, glycoproteins, polymers, or combinations thereof. Typically, proteins may be antibodies for a target protein. Typical polymers may be polyethylene glycol. WO 2007/031091 provides suitable moieties and conjugates, which are hereby incorporated by reference.

[0200] Accordingly, provided herein are conjugates comprising an oligomer as herein described, and at least one conjugated moiety that is not a nucleic acid or monomer, covalently attached to said oligomer. Therefore, in certain embodiments, where the oligomer of the invention consists of contiguous monomers having a specified sequence of bases, as herein disclosed, the conjugate may also comprise at least one conjugated moiety that is covalently attached to said oligomer.

[0201] In certain embodiments, the oligomer is conjugated to a moiety that increases the cellular uptake of oligomeric compounds.

[0202] In various embodiments, conjugates may enhance the activity, cellular distribution or cellular uptake of the oligomer of the invention. Such moieties include, but are not limited to, antibodies, polypeptides, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g. Hexyl-s-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipids, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-o-hexadecyl-rac-glycero-3-h-phosphonate, a polyamine or a polyethylene glycol chain, an adamantane acetic acid, a palmityl moiety, an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety.

[0203] In certain embodiments, the oligomers of the invention are conjugated to active drug substances, for example, aspirin, ibuprofen, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

[0204] In certain embodiments, the conjugated moiety is a sterol, such as cholesterol.

[0205] In various embodiments, the conjugated moiety comprises or consists of a positively charged polymer, such as a positively charged peptide of, for example 1-50, such as 2-20 such as 3-10 amino acid residues in length, and/or polyalkylene oxide such as polyethylene glycol (PEG) or polypropylene glycol--see WO 2008/034123, hereby incorporated by reference. Suitably, the positively charged polymer, such as a polyalkylene oxide may be attached to the oligomer of the invention via a linker such as the releasable inker described in WO 2008/034123.

[0206] Activated Oligomers

[0207] The term "activated oligomer," as used herein, refers to an oligomer of the invention that is covalently linked (i.e., functionalized) to at least one functional moiety that permits covalent linkage of the oligomer to one or more conjugated moieties, i.e., moieties that are not themselves nucleic acids or monomers, to form the conjugates herein described. Typically, a functional moiety will comprise a chemical group that is capable of covalently bonding to the oligomer via, e.g., a 3'-hydroxyl group or the exocyclic NH₂ group of the adenine base, a spacer that in some embodiments is hydrophilic and a terminal group that is capable of binding to a conjugated moiety (e.g., an amino, sulfhydryl or hydroxyl group). In some embodiments, this terminal group is not protected, e.g., is an NH₂ group. In other embodiments, the terminal group is protected, for example, by any suitable protecting group such as those described in "Protective Groups in Organic Synthesis" by Theodora W Greene and Peter G M Wuts, 3rd edition (John Wiley & Sons, 1999). Examples of suitable hydroxyl protecting groups include esters such as acetate ester, aralkyl groups such as benzyl, diphenylmethyl, or triphenylmethyl, and tetrahydropyranyl. Examples of suitable amino protecting groups include benzyl, alpha-methylbenzyl, diphenylmethyl, triphenylmethyl, benzyloxycarbonyl, tert-butoxycarbonyl, and acyl groups such as trichloroacetyl or trifluoroacetyl.

[0208] In some embodiments, the functional moiety is self-cleaving. In other embodiments, the functional moiety is biodegradable. See e.g., U.S. Pat. No. 7,087,229, which is incorporated by reference herein in its entirety.

[0209] In some embodiments, oligomers of the invention are functionalized at the 5' end in order to allow covalent attachment of the conjugated moiety to the 5' end of the oligomer. In other embodiments, oligomers of the invention can be functionalized at the 3' end. In still other embodiments, oligomers of the invention can be functionalized along the backbone or on the heterocyclic base moiety. In yet other embodiments, oligomers of the invention can be functionalized at more than one position independently selected from the 5' end, the 3' end, the backbone and the base.

[0210] In some embodiments, activated oligomers of the invention are synthesized by incorporating during the synthesis one or more monomers that is covalently attached to a functional moiety. In other embodiments, activated oligomers of the invention are synthesized with monomers that have not been functionalized, and the oligomer is functionalized upon completion of synthesis.

[0211] In some embodiments, the oligomers are functionalized with a hindered ester containing an aminoalkyl linker, wherein the alkyl portion has the formula (CH₂)_w, wherein w is an integer ranging from 1 to 10, preferably about 6, wherein the alkyl portion of the alkylamino group can be straight chain or branched chain, and wherein the functional group is attached to the oligomer via an ester group (--O--C(O)--(CH₂)_wNH).

[0212] In other embodiments, the oligomers are functionalized with a hindered ester containing a (CH₂)_w-sulfhydryl (SH) linker, wherein w is an integer ranging from 1 to 10, preferably about 6, wherein the alkyl portion of the alkylamino group can be straight chain or branched chain, and wherein the functional group attached to the oligomer via an ester group (--O--C(O)--(CH₂)_wSH). In some embodiments, sulfhydryl-activated oligonucleotides are conjugated with polymer moieties such as polyethylene glycol or peptides (via formation of a disulfide bond).

[0213] Activated oligomers covalently linked to at least one functional moiety can be synthesized by any method known in the art, and in particular by methods disclosed in U.S. Patent Publication No. 2004/0235773, which is incorporated herein by reference in its entirety, and in Zhao et al. (2007) J. Controlled Release 119:143-152; and Zhao et al. (2005) Bioconjugate Chem. 16:758-766.

[0214] In still other embodiments, the oligomers of the invention are functionalized by introducing sulfhydryl, amino or hydroxyl groups into the oligomer by means of a functionalizing reagent substantially as described in U.S. Pat. Nos. 4,962,029 and 4,914,210, i.e., a substantially linear reagent having a phosphoramidite at one end linked through a hydrophilic spacer chain to the opposing end which comprises a protected or unprotected sulfhydryl, amino or hydroxyl group. Such reagents primarily react with hydroxyl groups of the oligomer. In some embodiments, such activated oligomers have a functionalizing reagent coupled to a 5'-hydroxyl group of the oligomer. In other embodiments, the activated oligomers have a functionalizing reagent coupled to a 3'-hydroxyl group. In still other embodiments, the activated oligomers of the invention have a functionalizing reagent coupled to a hydroxyl group on the backbone of the oligomer. In yet further embodiments, the oligomer of the invention is functionalized with more than one of the functionalizing reagents as described in U.S. Pat. Nos. 4,962,029 and 4,914,210, incorporated herein by reference in their entirety. Methods of synthesizing such functionalizing reagents and incorporating them into monomers or oligomers are disclosed in U.S. Pat. Nos. 4,962,029 and 4,914,210.

[0215] In some embodiments, the 5'-terminus of a solid-phase bound oligomer is functionalized with a dienyl phosphoramidite derivative, followed by conjugation of the deprotected oligomer with, e.g., an amino acid or peptide via a Diels-Alder cycloaddition reaction.

[0216] In various embodiments, the incorporation of monomers containing 2'-sugar modifications, such as a 2'-carbamate substituted sugar or a 2'-(O-pentyl-N-phthalimido)-deoxyribose sugar into the oligomer facilitates covalent attachment of conjugated moieties to the sugars of the oligomer. In other embodiments, an oligomer with an amino-containing linker at the 2'-position of one or more monomers is prepared using a reagent such as, for example, 5'-dimethoxytrityl-2'-O-(e-phthalimidylaminopentyl)-2'-deoxyadenosine-3'-- N,N-diisopropyl-cyanoethoxy phosphoramidite. See, e.g., Manoharan, et al., Tetrahedron Letters, 1991, 34, 7171.

[0217] In still further embodiments, the oligomers of the invention have amine-containing functional moieties on the nucleobase, including on the N6 purine amino groups, on the exocyclic N2 of guanine, or on the N4 or 5 positions of cytosine. In some embodiments, such functionalization may be achieved by using a commercial reagent that is already functionalized in the oligomer synthesis.

[0218] Some functional moieties are commercially available, for example, heterobifunctional and homobifunctional linking moieties are available from the Pierce Co. (Rockford, Ill.). Other commercially available linking groups are 5'-Amino-Modifier C6 and 3'-Amino-Modifier reagents, both available from Glen Research Corporation (Sterling, Va.). 5'-Amino-Modifier C6 is also available from ABI (Applied Biosystems Inc., Foster City, Calif.) as Aminolink-2, and 3'-Amino-Modifier is also available from Clontech Laboratories Inc. (Palo Alto, Calif.).

Compositions

[0219] In various embodiments, the oligomer of the invention is used in pharmaceutical formulations and compositions. Suitably, such compositions comprise a pharmaceutically acceptable diluent, carrier, salt or adjuvant. WO2007/031091 provides suitable and preferred pharmaceutically acceptable diluents, carriers and adjuvants--which are hereby incorporated by reference. Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in WO2007/031091--which are also hereby incorporated by reference. Details on techniques for formulation and administration also may be found in the latest edition of "REMINGTON'S PHARMACEUTICAL SCIENCES" (Maack Publishing Co, Easton Pa.).

[0220] In some embodiments, an oligomer of the invention is covalently linked to a conjugated moiety to aid in delivery of the oligomer across cell membranes. An example of a conjugated moiety that aids in delivery of the oligomer across cell membranes is a lipophilic moiety, such as cholesterol. In various embodiments, an oligomer of the invention is formulated with lipid formulations that form liposomes, such as Lipofectamine 2000 or Lipofectamine RNAiMAX, both of which are commercially available from Invitrogen. In some embodiments, the oligomers of the invention are formulated with a mixture of one or more lipid-like non-naturally occurring small molecules ("lipidoids"). Libraries of lipidoids can be synthesized by conventional synthetic chemistry methods and various amounts and combinations of lipidoids can be assayed in order to develop a vehicle for effective delivery of an oligomer of a particular size to the targeted tissue by the chosen route of administration. Suitable lipidoid libraries and compositions can be found, for example in Akinc et al. (2008) Nature Biotechnol., available at http://www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt11402.html, which is incorporated by reference herein.

[0221] As used herein, the term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the herein identified compounds and exhibit acceptable levels of undesired toxic effects. Non-limiting examples of such salts can be formed with organic amino acid and base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a cation formed from ammonia, N,N'-dibenzylethylene-diamine, D-glucosamine, tetraethylammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like.

Applications

[0222] The term "treatment" as used herein refers to both treatment of an existing disease (e.g., a disease or disorder as referred to herein below), or prevention of a disease, i.e., prophylaxis. It will therefore be recognised that, in certain embodiments, "treatment" includes prophylaxis.

[0223] In various embodiments, the oligomers of the invention may be utilized as research reagents for, for example, diagnostics, therapeutics and prophylaxis.

[0224] In some embodiments, such oligomers may be used for research purposes to specifically inhibit the expression of HER3 (and/or HER2 and/or EGFR) protein (typically, by degrading or inhibiting the HER3 (and/or HER2 and/or EGFR) mRNA and thereby preventing protein formation) in cells and experimental animals, thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention.

[0225] In certain embodiments, the oligomers may be used in diagnostics to detect and quantitate HER3 (and/or HER2 and/or EGFR) expression in cells and tissues by northern blotting, in-situ hybridisation or similar techniques.

[0226] In various therapeutic embodiments, a non-human animal or a human, suspected of having a disease or disorder, which can be treated by modulating the expression of HER3 (and optionally HER2 and/or EGFR) is treated by administering an effective amount of an oligomer (or conjugate thereof) in accordance with this invention. Further provided are methods of treating a mammal, such as treating a human, suspected of having or being prone to a disease or condition, associated with expression of HER3 (and/or HER2 and/or EGFR) by administering a therapeutically or prophylactically effective amount of one or more of the oligomers or compositions of the invention.

[0227] In certain embodiments, the invention also provides for the use of the compounds or conjugates of the invention as described for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of a disorder as referred to herein.

[0228] In various embodiments, the invention also provides for a method for treating a disorder as referred to herein said method comprising administering a compound according to the invention as herein described, and/or a conjugate according to the invention, and/or a pharmaceutical composition according to the invention to a patient in need thereof.

[0229] In various embodiments, the invention relates to an oligomer, a composition or a conjugate thereof as described herein for use as a medicament.

[0230] In various embodiments, the invention provides for a method for treating a disorder as referred to herein, the method comprising administering an effective amount of a compound according to the invention as herein described, and/or an effective amount of a conjugate according to the invention, and/or a pharmaceutical composition according to the invention to a patient in need thereof.

[0231] In various embodiments, the oligomer, or conjugate thereof, induces a desired therapeutic effect in humans through, for example, hydrogen bonding to a target nucleic acid. The oligomer causes a decrease (e.g., inhibition) in the expression of a target via hydrogen bonding (e.g., hybridisation) to the mRNA of the target thereby resulting in a reduction in gene expression.

[0232] It is highly preferred that the compounds of the invention are capable of hybridising to the target nucleic acid, such as HER3 mRNA, by Watson-Crick base pairing.

Medical Indications

[0233] In certain therapeutic embodiments, the disorder to be treated is selected from the group consisting of a hyperproliferative disorder, such as cancer, such as a cancer selected from the group consisting of lymphomas and leukemias (e.g. non-Hodgkin's lymphoma, Hodgkin's lymphoma, acute leukemia such as acute lymphocytic leukemia, acute myelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma), colon carcinoma, rectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, cervical cancer, testicular cancer, lung carcinoma, bladder carcinoma, melanoma, head and neck cancer, brain cancer, cancers of unknown primary site, neoplasms, cancers of the peripheral nervous system, cancers of the central nervous system, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumour, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, seminoma, embryonal carcinoma, Wilms' tumour, small cell lung carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, and retinoblastoma, heavy chain disease, metastases, or any disease or disorder characterized by uncontrolled or abnormal cell growth.

[0234] In certain embodiments, the disease is a cancer selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, and brain cancer.

[0235] In certain other embodiments, the disease is a mammary carcinoma.

[0236] In various embodiments, the treatment of such a disease or condition according to the invention may be combined with one or more other anti-cancer treatments, such as radiotherapy, chemotherapy or immunotherapy.

[0237] In certain embodiments, the disease or disorder is associated with a mutation in the HER3 gene (and/or the HER2 gene and/or the EGFR gene) or a gene whose protein product is associated with or interacts with HER3. Therefore, in various embodiments, the target mRNA is a mutated form of the HER3 sequence; for example, it comprises one or more single point mutations, such as SNPs associated with cancer.

[0238] In certain embodiments, the disease or disorder is associated with abnormal levels of a mutated form of HER3. In certain embodiments, the disease or disorder is associated with abnormal levels of a wild-type form of HER3. One aspect of the invention is directed to a method of treating a mammal suffering from or susceptible to conditions associated with abnormal levels of HER3, comprising administering to the mammal a therapeutically effective amount of an oligomer of the invention targeted to HER3 or various conjugates thereof. In some embodiments, the oligomer comprises one or more LNA units.

[0239] In various embodiments, the invention is directed to a method of treating a mammal suffering from or susceptible to conditions associated with abnormal levels of a mutated form of HER2, or abnormal levels of a wild-type form of HER2, comprising administering to the mammal a therapeutically effective amount of an oligomer of the invention targeted to HER3 (and/or to HER2 and/or to EGFR) or various conjugates thereof. In some embodiments, the oligomer comprises one or more LNA units.

[0240] In still other embodiments, the invention is directed to a method of treating a mammal suffering from or susceptible to conditions associated with abnormal levels of a mutated EGFR, or abnormal levels of a wild-type EGFR, comprising administering to the mammal a therapeutically effective amount of an oligomer of the invention targeted to HER3 (and/or to HER2 and/or to EGFR). In some embodiments, the oligomer comprises one or more LNA units.

[0241] Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, prodrug formulations are also provided in WO 2007/031091, which is hereby incorporated by reference. The invention also provides for a pharmaceutical composition comprising a compound or a conjugate as herein described or a conjugate and a pharmaceutically acceptable diluent, carrier or adjuvant. WO 2007/031091 provides suitable and preferred pharmaceutically acceptable diluents, carriers and adjuvants, which are hereby incorporated by reference.

[0242] In various embodiments, the invention described herein encompasses a method of preventing or treating a disease comprising administering a therapeutically effective amount of a HER3 modulating oligomer (and/or a HER2 modulating oligomer and/or an EGFR modulating oligomer) to a human in need of such therapy. The invention further encompasses the use of a short period of administration of a HER3 modulating oligonucleotide compound (oligomer or conjugate) (and/or a HER2 modulating oligomer and/or an EGFR modulating oligomer).

Combination with Other Antisense Oligomers In some embodiments, oligomers of the invention are targeted to HER3, HER2 and/or EGFR nucleic acids. Thus, in some embodiments, the invention relates to the use of more than one oligomer to target two or even all three target nucleic acids. In various embodiments, an oligomer which targets HER3 is administered with a second oligomer which targets either EGFR or HER2. In various other embodiments, an oligomer which targets HER3 is administered with a second oligomer which targets HER2 and a third oligomer that targets EGFR. Such oligomers can be administered concurrently, or sequentially.

[0243] In various embodiments the invention relates to a pharmaceutical composition that comprises an oligomer targeted to HER3, and a further therapeutic agent which targets and down-regulates HER2 expression, such as an antisense oligomer which targets HER2 mRNA.

[0244] In other embodiments, which may be the same or different, the invention relates to a pharmaceutical composition comprising an oligomer targeted to HER3, and a further therapeutic agent which targets and down-regulates EGFR expression, such as an antisense oligomer which target EGFR mRNA.

[0245] In some embodiments, oligomers that target HER2 and/or EGFR mRNA (or conjugates thereof), have the same designs (e.g., gapmers, headmers, tailmers) as oligomers that target HER3. In various embodiments, oligomers that target HER2 and/or EGFR mRNA (or conjugates thereof), have different designs from oligomers that target HER3.

Kits

[0246] The invention also provides a kit comprising a first component and a second component. In various embodiments, said first component comprises an oligomer of the invention that is capable of inhibiting (e.g., by down-regulating) expression of HER3, or a conjugate and/or pharmaceutical composition thereof. In other embodiments, the second component comprises a second active ingredient. In some embodiments, the second component is a therapeutic agent that is an oligonucleotide as described herein. In other embodiments, the therapeutic agent is other than an oligonucleotide (e.g., a small molecule therapeutic agent such as taxol). In some embodiments, kits of the invention are used in methods of treating a hyperproliferative disorder, such as cancer, which comprises administering to a patient in need thereof an effective amount of a first component and a second component of the kit. In various embodiments, the first and second components are administered simultaneously. In other embodiments, the first and second components are administered sequentially and in any order.

[0247] In some embodiments, the kit comprises a first component that comprises an oligomer of the invention that is capable of inhibiting (e.g., by down-regulating) expression of HER3, or a conjugate and/or pharmaceutical composition thereof, and a second component that is an antisense oligonucleotide capable of inhibiting (e.g., by down-regulating) the expression of HER2 and/or EGFR expression as described herein, or a conjugate and/or pharmaceutical composition thereof.

FURTHER EMBODIMENTS

[0248] The following embodiments also relate to the description and summary of the invention, and may be combined with the embodiments of the invention referred to therein including the embodiments referred to in the claims:

1. An antisense oligonucleotide capable of binding to a target sequence of the HER3 gene of SEQ ID NO: 197 or allele thereof and down-regulating expression of HER3, said oligonucleotide comprising a sequence of 10-50 nucleobases corresponding to the target sequence. 2. The antisense oligonucleotide of embodiment 1, wherein the target sequence is selected from regions of the HER3 gene represented by SEQ ID NOS: 1-140 or an allelic variant thereof. 3. The oligonucleotide of embodiment 1 or embodiment 2 comprising a sequence of 10-16 nucleobases shown in SEQ ID NOS: 1, 16, 17, 18, 19, 34, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 74, 75, 76, 91, 92, 107, 122, 137, 138, 139 and 140 or an allelic variant thereof. 4. The oligonucleotide according to any one of embodiments 1-3 comprising any one of the sequences shown as SEQ ID NOS: 1-140. 5. The oligonucleotide of any one of the preceding embodiments represented by SEQ ID NOS: 141-196. 6. The oligonucleotide of embodiment 1, wherein said oligonucleotide is further capable of down-regulating expression of the HER2 gene of SEQ ID NO: 199, or an allelic variant thereof, and/or the EGFR gene of SEQ ID NO:198, or an allelic variant thereof. 7. The oligonucleotide of embodiment 6, wherein said oligonucleotide is capable of down-regulating the expression of the HER2 gene of SEQ ID NO: 199, or an allelic variant thereof, and wherein the oligonucleotide is represented by SEQ ID NO: 177 or 178. 8. The oligonucleotide of embodiment 6, wherein said oligonucleotide is capable of down-regulating the expression of the EGFR gene of SEQ ID NO: 198, or an allelic variant thereof, and wherein the oligonucleotide is represented by SEQ ID NO: 171 or 173. 9. The oligonucleotide of embodiment 6, wherein said oligonucleotide is capable of down-regulating expression of the HER2 gene of SEQ ID NO: 199, or an allelic variant thereof, and the EGFR gene of SEQ ID NO: 198, or an allelic variant thereof. 10. The oligonucleotide of embodiment 9, wherein said oligonucleotide is represented by any one of SEQ ID NOS: 169, 170, 172, 174, 175, 176 and 179. 11. The oligonucleotide according to any one of the preceding embodiments, wherein said nucleobase sequence comprises internucleobase linkages independently selected from phosphodiester, phosphorothioate and boranophosphate. 12. The oligonucleotide of any one of the preceding embodiments, wherein at least two of said nucleobases are nucleotide analogues. 13. The oligonucleotide according to embodiment 5, wherein said sequence of nucleobases comprises, in a 5' to 3' direction (i) region A: a stretch of 2-4 nucleotide analogues, followed by (ii) region B: a stretch of 6-11 nucleotides or nucleotide analogues different from those of region A, followed by (iii) region C: a stretch of 2-4 nucleotide analogues, and optionally followed by (iv) region D: one or two nucleotides. 14. The oligonucleotide according to embodiment 13, wherein the region A comprises at least one phosphodiester linkage between two nucleotide analogue units and/or or a nucleotide analogue unit and a nucleobase unit of Region B. 15. The oligonucleotide according to embodiment 13 or embodiment 14, wherein region C comprises at least one phosphodiester linkage between two nucleotide analogue units and/or a nucleotide analogue unit and a nucleobase unit of Region B. 16. The oligonucleotide according to any one of embodiments 1 to 11, wherein all the internucleobase linkages are phosphorothioate. 17. The oligonucleotide according to any one of embodiments 12 to 16, wherein said nucleotide analogue units are independently selected from 2'-O-alkyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, locked nucleic acid (LNA), arabino nucleic acid (ANA), 2'-fluoro-ANA, HNA, intercalating nucleic acid (INA) and 2'-MOE. 18. The oligonucleotide according to embodiment 17, wherein the nucleotide analogues are independently selected from 2'-MOE-RNA, 2'-fluoro-DNA, and LNA. 19. The oligonucleotide according to embodiment 18, wherein at least one of said nucleotide analogues is a locked nucleic acid (LNA). 20. The oligonucleotide according to embodiment 19, wherein all the nucleotide analogues are LNA. 21. The oligonucleotide according to any one of embodiments 17 to 20, wherein LNA is selected from beta-D-oxy-LNA, alpha-L-oxy-LNA, beta-D-amino-LNA and beta-D-thio-LNA. 22. A conjugate comprising an oligonucleotide of any one of the preceding embodiments and at least one non-nucleotide or non-polynucleotide moiety covalently attached to said oligonucleotide. 23. A conjugate according to embodiment 22, wherein said non-nucleotide or non-polynucleotide moiety consists of or comprises a sterol group, for example cholesterol. 24. A pharmaceutical composition comprising an oligonucleotide according to any one of the embodiments 1 to 21 or a conjugate according to embodiment 22 or embodiment 23, and a pharmaceutically acceptable diluent, carrier or adjuvant. 25. An oligonucleotide or a conjugate according to any one of embodiments 1 to 23 for use as a medicament. 26. Use of an oligonucleotide or a conjugate according to any one of embodiments 1 to 23 for the manufacture of a medicament for the treatment of abnormal levels of HER3 and/or HER2 and/or EGFR or a disease or condition for which down-regulation of HER3 and/or HER2 and/or EGFR expression is indicated. 27. The use according to embodiment 26, wherein said disease or condition is cancer. 28. A method of treating a subject suffering from cancer, the method comprising the step of administering a pharmaceutical composition, oligonucleotide or conjugate according to any one of embodiments 1 to 24 to the subject in need thereof. 29. The use or the method of embodiment 27 or 28, wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer and brain cancer. 30. A target sequence within the HER3 gene, wherein an antisense oligonucleotide corresponding to said target sequence is capable of down-regulating the expression of HER3. 31. The target sequence of embodiment 30, wherein the target sequence is selected from the regions of the HER3 gene complementary to SEQ ID NOs 1-140 or allelic variants thereof. 32. A method of down-regulating the expression of HER3 in a cell, comprising contacting the cell with an oligonucleotide according to any one of embodiments 1-21.

EXAMPLES

Example 1

Monomer Synthesis

[0249] The LNA monomer building blocks and derivatives thereof were prepared according to published procedures. See WO07/031,081 and the references cited therein.

Example 2

Oligonucleotide Synthesis

[0250] Oligonucleotides were synthesized according to the method described in WO07/031,081. Table 1 shows examples of antisense oligonucleotide motifs of the invention.

Example 3

Design of the Oligonucleotides

[0251] In accordance with the invention, a series of oligonucleotides were designed to target different regions of human EGFR (GenBank Accession number NM_--005228, SEQ ID NO: 198) and human HER2 (GenBank Accession number NM_--004448, SEQ ID NO: 199) in addition to human HER3 (GenBank Accession number NM_--001982, SEQ ID NO: 197).

[0252] Of the sequences shown in Table 1, below, SEQ ID NOs: 1-50, 53, 139 and 140 were designed to target human EGFR and human HER2 in addition to human HER3. The percentage of sequence homology with HER3, EGFR and HER2 is indicated. The sequences of the oligomers contain 0-2 mismatches when compared to the sequences of the best-aligned target regions of EGFR, and 1-2 mismatches when compared to the sequences of the best-aligned target regions of HER2.

TABLE-US-00001 TABLE 1 Antisense Oligonucleotide Sequences Length Target site Compl Compl SEQ ID NO Sequence (5'-3') (bases) HER3 EGFR HER2 SEQ ID NO: 1 GCTCCAGACATCACTC 16 2866-2881 100% 87.5% SEQ ID NO: 2 GCTCCAGACATCACT 15 SEQ ID NO: 3 CTCCAGACATCACTC 15 SEQ ID NO: 4 GCTCCAGACATCAC 14 SEQ ID NO: 5 CTCCAGACATCACT 14 SEQ ID NO: 6 TCCAGACATCACTC 14 SEQ ID NO: 7 GCTCCAGACATCA 13 SEQ ID NO: 8 CTCCAGACATCAC 13 SEQ ID NO: 9 TCCAGACATCACT 13 SEQ ID NO: 10 CCAGACATCACTC 13 SEQ ID NO: 11 GCTCCAGACATC 12 SEQ ID NO: 12 CTCCAGACATCA 12 SEQ ID NO: 13 TCCAGACATCAC 12 SEQ ID NO: 14 CCAGACATCACT 12 SEQ ID NO: 15 CAGACATCACTC 12 SEQ ID NO: 16 CTCCAGACATCACTCT 16 2865-2880 100% 93.8% SEQ ID NO: 17 CAGACATCACTCTGGT 16 2862-2877 100% 93.8% SEQ ID NO: 18 AGACATCACTCTGGTG 16 2861-2876 100% 93.8% SEQ ID NO: 19 ATAGCTCCAGACATCA 16 2869-2884 93.8% 87.5% SEQ ID NO: 20 ATAGCTCCAGACATC 15 SEQ ID NO: 21 TAGCTCCAGACATCA 15 SEQ ID NO: 22 ATAGCTCCAGACAT 14 SEQ ID NO: 23 TAGCTCCAGACATC 14 SEQ ID NO: 24 AGCTCCAGACATCA 14 SEQ ID NO: 25 ATAGCTCCAGACA 13 SEQ ID NO: 26 TAGCTCCAGACAT 13 SEQ ID NO: 27 AGCTCCAGACATC 13 SEQ ID NO: 28 GCTCCAGACATCA 13 SEQ ID NO: 29 ATAGCTCCAGAC 12 SEQ ID NO: 30 TAGCTCCAGACA 12 SEQ ID NO: 31 AGCTCCAGACAT 12 SEQ ID NO: 32 GCTCCAGACATC 12 SEQ ID NO: 33 CTCCAGACATCA 12 SEQ ID NO: 34 TCACACCATAGCTCCA 16 2876-2891 87.5% 93.8% SEQ ID NO: 35 TCACACCATAGCTCC 15 SEQ ID NO: 36 CACACCATAGCTCCA 15 SEQ ID NO: 37 TCACACCATAGCTC 14 SEQ ID NO: 38 CACACCATAGCTCC 14 SEQ ID NO: 39 ACACCATAGCTCCA 14 SEQ ID NO: 40 TCACACCATAGCT 13 SEQ ID NO: 41 CACACCATAGCTC 13 SEQ ID NO: 42 ACACCATAGCTCC 13 SEQ ID NO: 43 CACCATAGCTCCA 13 SEQ ID NO: 44 TCACACCATAGC 12 SEQ ID NO: 45 CACACCATAGCT 12 SEQ ID NO: 46 ACACCATAGCTC 12 SEQ ID NO: 47 CACCATAGCTCC 12 SEQ ID NO: 48 ACCATAGCTCCA 12 SEQ ID NO: 49 CATCCAACACTTGACC 16 3025-3040 93.8% 93.8% SEQ ID NO: 50 ATCCAACACTTGACCA 16 3024-3039 93.8% 93.8% SEQ ID NO: 51 CAATCATCCAACACTT 16 3029-3044 87.5% 93.8% SEQ ID NO: 52 TCAATCATCCAACACT 16 3030-3045 87.5% 93.8% SEQ ID NO: 53 CATGTAGACATCAATT 16 3004-3019 87.5% 93.8% SEQ ID NO: 54 TAGCCTGTCACTTCTC 16 435-450 68.8% 75% SEQ ID NO: 228 TAGCCTGTCACTTCT 15 SEQ ID NO: 229 AGCCTGTCACTTCTC 15 SEQ ID NO: 230 TAGCCTGTCACTTC 14 SEQ ID NO: 231 AGCCTGTCACTTCT 14 SEQ ID NO: 232 TAGCCTGTCACTT 13 SEQ ID NO: 233 TAGCCTGTCACT 12 SEQ ID NO: 55 AGATGGCAAACTTCCC 16 530-545 68.8% 68.8% SEQ ID NO: 56 CAAGGCTCACACATCT 16 1146-1161 75% 68.8% SEQ ID NO: 57 AAGTCCAGGTTGCCCA 16 1266-1281 75% 75% SEQ ID NO: 58 CATTCAAGTTCTTCAT 16 1490-1505 75% 68.8% SEQ ID NO: 59 CACTAATTTCCTTCAG 16 1529-1544 81.3% 68.8% SEQ ID NO: 60 CACTAATTTCCTTCA 15 SEQ ID NO: 61 ACTAATTTCCTTCAG 15 SEQ ID NO: 62 CACTAATTTCCTTC 14 SEQ ID NO: 63 ACTAATTTCCTTCA 14 SEQ ID NO: 64 CTAATTTCCTTCAG 14 SEQ ID NO: 65 CACTAATTTCCTT 13 SEQ ID NO: 66 ACTAATTTCCTTC 13 SEQ ID NO: 67 CTAATTTCCTTCA 13 SEQ ID NO: 68 TAATTTCCTTCAG 13 SEQ ID NO: 69 CACTAATTTCCT 12 SEQ ID NO: 70 ACTAATTTCCTT 12 SEQ ID NO: 71 CTAATTTCCTTC 12 SEQ ID NO: 72 TAATTTCCTTCA 12 SEQ ID NO: 73 AATTTCCTTCAG 12 SEQ ID NO: 74 GCCCAGCACTAATTTC 16 1535-1550 75% 68.8% SEQ ID NO: 75 CTTTGCCCTCTGCCAC 16 1673-1688 75% 75% SEQ ID NO: 76 CACACACTTTGCCCTC 16 1679-1694 68.8% 75% SEQ ID NO: 77 CACACACTTTGCCCT 15 SEQ ID NO: 78 ACACACTTTGCCCTC 15 SEQ ID NO: 79 CACACACTTTGCCC 14 SEQ ID NO: 80 ACACACTTTGCCCT 14 SEQ ID NO: 81 CACACTTTGCCCTC 14 SEQ ID NO: 82 CACACACTTTGCC 13 SEQ ID NO: 83 ACACACTTTGCCC 13 SEQ ID NO: 84 CACACTTTGCCCT 13 SEQ ID NO: 85 ACACTTTGCCCTC 13 SEQ ID NO: 86 CACACACTTTGC 12 SEQ ID NO: 87 ACACACTTTGCC 12 SEQ ID NO: 88 CACACTTTGCCC 12 SEQ ID NO: 89 ACACTTTGCCCT 12 SEQ ID NO: 90 CACTTTGCCCTC 12 SEQ ID NO: 91 CAGTTCCAAAGACACC 16 2345-2360 75% 68.8% SEQ ID NO: 92 TGGCAATTTGTACTCC 16 2636-2651 75% 68.8% SEQ ID NO: 93 TGGCAATTTGTACTC 15 SEQ ID NO: 94 GGCAATTTGTACTCC 15 SEQ ID NO: 95 TGGCAATTTGTACT 14 SEQ ID NO: 96 GGCAATTTGTACTC 14 SEQ ID NO: 97 GCAATTTGTACTCC 14 SEQ ID NO: 98 TGGCAATTTGTAC 13 SEQ ID NO: 99 GGCAATTTGTACT 13 SEQ ID NO: 100 GCAATTTGTACTC 13 SEQ ID NO: 101 CAATTTGTACTCC 13 SEQ ID NO: 102 TGGCAATTTGTA 12 SEQ ID NO: 103 GGCAATTTGTAC 12 SEQ ID NO: 104 GCAATTTGTACT 12 SEQ ID NO: 105 CAATTTGTACTC 12 SEQ ID NO: 106 AATTTGTACTCC 12 SEQ ID NO: 107 GTGTGTGTATTTCCCA 16 2848-2863 75% 68.8% SEQ ID NO: 108 GTGTGTGTATTTCCC 15 SEQ ID NO: 109 TGTGTGTATTTCCCA 15 SEQ ID NO: 110 GTGTGTGTATTTCC 14 SEQ ID NO: 111 TGTGTGTATTTCCC 14 SEQ ID NO: 112 GTGTGTATTTCCCA 14 SEQ ID NO: 113 GTGTGTGTATTTC 13 SEQ ID NO: 114 TGTGTGTATTTCC 13 SEQ ID NO: 115 GTGTGTATTTCCC 13 SEQ ID NO: 116 TGTGTATTTCCCA 13

SEQ ID NO: 117 GTGTGTGTATTT 12 SEQ ID NO: 118 TGTGTGTATTTC 12 SEQ ID NO: 119 GTGTGTATTTCC 12 SEQ ID NO: 120 TGTGTATTTCCC 12 SEQ ID NO: 121 GTGTATTTCCCA 12 SEQ ID NO: 122 CCCTCTGATGACTCTG 16 3474-3489 68.8% 68.8% SEQ ID NO: 123 CCCTCTGATGACTCT 15 SEQ ID NO: 124 CCTCTGATGACTCTG 15 SEQ ID NO: 125 CCCTCTGATGACTC 14 SEQ ID NO: 126 CCTCTGATGACTCT 14 SEQ ID NO: 127 CTCTGATGACTCTG 14 SEQ ID NO: 128 CCCTCTGATGACT 13 SEQ ID NO: 129 CCTCTGATGACTC 13 SEQ ID NO: 130 CTCTGATGACTCT 13 SEQ ID NO: 131 TCTGATGACTCTG 13 SEQ ID NO: 132 CCCTCTGATGAC 12 SEQ ID NO: 133 CCTCTGATGACT 12 SEQ ID NO: 134 CTCTGATGACTC 12 SEQ ID NO: 135 TCTGATGACTCT 12 SEQ ID NO: 136 CTGATGACTCTG 12 SEQ ID NO: 137 CATACTCCTCATCTTC 16 3770-3785 81.3% 81.3% SEQ ID NO: 138 CCACCACAAAGTTATG 16 1067-1082 81.3% 68.8% SEQ ID NO: 139 CATCACTCTGGTGTGT 16 2858-2873 93.8% 93.8% SEQ ID NO: 140 GACATCACTCTGGTGT 16 2860-2875 93.8% 87.5%

[0253] In Table 2, bold letters represent shorter sequences shown in Table 1.

TABLE-US-00002 TABLE 2 HER3 24mer Sequences Corresponding 24mer sequence 16mer SEQ IDs comprising 16mer 24mer SEQ ID SEQ ID NO: 1 catagctccagacatcactc SEQ ID NO: 200 tggt SEQ ID NO: 16 atagctccagacatcactct SEQ ID NO: 201 ggtg SEQ ID NO: 17 gctccagacatcactctggt SEQ ID NO: 202 gtgt SEQ ID NO: 18 ctccagacatcactctggtg SEQ ID NO: 203 tgtg SEQ ID NO: 19 caccatagctccagacatca SEQ ID NO: 204 ctct SEQ ID NO: 34 actgtcacaccatagctcca SEQ ID NO: 205 gaca SEQ ID NO: 49 caatcatccaacacttgacc SEQ ID NO: 206 atca SEQ ID NO: 50 aatcatccaacacttgacca SEQ ID NO: 207 tcac SEQ ID NO: 51 tcatcaatcatccaacactt SEQ ID NO: 208 gacc SEQ ID NO: 52 ctcatcaatcatccaacact SEQ ID NO: 209 tgac SEQ ID NO: 53 tcaccatgtagacatcaatt SEQ ID NO: 210 gtgc SEQ ID NO: 54 gacatagcctgtcacttctc SEQ ID NO: 211 gaat SEQ ID NO: 55 acgaagatggcaaacttccc SEQ ID NO: 212 atcg SEQ ID NO: 56 cccacaaggctcacacatct SEQ ID NO: 213 tgag SEQ ID NO: 57 cagaaagtccaggttgccca SEQ ID NO: 214 ggat SEQ ID NO: 58 gtgacattcaagttcttcat SEQ ID NO: 215 gatc SEQ ID NO: 59 ccagcactaatttccttcag SEQ ID NO: 216 ggat SEQ ID NO: 74 atacgcccagcactaatttc SEQ ID NO: 217 cttc SEQ ID NO: 75 cacactttgccctctgccac SEQ ID NO: 218 gcag SEQ ID NO: 76 gggtcacacactttgccctc SEQ ID NO: 219 tgcc SEQ ID NO: 91 tgcacagttccaaagacacc SEQ ID NO: 220 cgag SEQ ID NO: 92 cccttggcaatttgtactcc SEQ ID NO: 221 ccag SEQ ID NO: 107 tctggtgtgtgtatttccca SEQ ID NO: 222 aagt SEQ ID NO: 122 atgcccctctgatgactctg SEQ ID NO: 223 atgc SEQ ID NO: 137 tattcatactcctcatcttc SEQ ID NO: 224 atct SEQ ID NO: 138 tgatccaccacaaagttatg SEQ ID NO: 225 ggga SEQ ID NO: 139 cagacatcactctggtgtgt SEQ ID NO: 226 gtat SEQ ID NO: 140 tccagacatcactctggtgt SEQ ID NO: 227 gtgt

[0254] In SEQ ID NOs: 141-168 shown in Table 3, uppercase letters indicate nucleoside analogue monomers and the subscript "s" represents a phosphorothioate linkage. Lowercase letters represent DNA monomers. The absence of "s" between monomers (if any) indicates a phosphodiester linkage.

TABLE-US-00003 TABLE 3 Oligonucleotide gapmers SEQ ID NO Sequence (5'-3') SEQ ID NO: c_{scsasgsascsastscsas} C 141 SEQ ID NO: c_{sasgsascsastscsascs} T 142 SEQ ID NO: a_{scsastscsascstscsts} T 143 SEQ ID NO: c_{sastscsascstscstsgs} G 144 SEQ ID NO: g_{scstscscsasgsascsas} A 145 SEQ ID NO: c_{sascscsastsasgscsts} A 146 SEQ ID NO: c_{scsasascsascststsgs} C 147 SEQ ID NO: c_{sasascsascststsgsas} A 148 SEQ ID NO: t_{scsastscscsasascsas} T 149 SEQ ID NO: a_{stscsastscscsasascs} T 150 SEQ ID NO: g_{stsasgsascsastscsas} T 151 SEQ ID NO: c_{scstsgstscsascststs} C 152 SEQ ID NO: t_{sgsgscsasasascststs} C 153 SEQ ID NO: g_{sgscstscsascsascsas} T 154 SEQ ID NO: t_{scscsasgsgststsgscs} A 155 SEQ ID NO: t_{scsasasgststscststs} T 156 SEQ ID NO: t_{sasastststscscststs} G 157 SEQ ID NO: c_{sasgscsascstsasasts} C 158 SEQ ID NO: t_{sgscscscstscstsgscs} C 159 SEQ ID NO: a_{scsascstststsgscscs} C 160 SEQ ID NO: t_{stscscsasasasgsascs} C 161 SEQ ID NO: c_{sasastststsgstsascs} C 162 SEQ ID NO: t_{sgstsgstsastststscs} A 163 SEQ ID NO: t_{scstsgsastsgsascsts} G 164 SEQ ID NO: a_{scstscscstscsastscs} C 165 SEQ ID NO: c_{scsascsasasasgststs} G 166 SEQ ID NO: c_{sascstscstsgsgstsgs} T 167 SEQ ID NO: a_{stscsascstscstsgsgs} T 168

Example 4

In Vitro Model

Cell Culture

[0255] The effect of antisense oligonucleotides on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. The target can be expressed endogenously or by transient or stable transfection of a nucleic acid encoding said target. The expression level of target nucleic acid can be routinely determined using, for example, Northern blot analysis, Real-Time PCR, or ribonuclease protection assays. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the chosen cell type.

[0256] Cells were cultured in the appropriate medium as described below and maintained at 37° C. at 95-98% humidity and 5% CO₂. Cells were routinely passaged 2-3 times weekly.

[0257] 15PC3: The human prostate cancer cell line 15PC3 was cultured in DMEM (Sigma)+10% fetal bovine serum (FBS)+2 mM Glutamax I+gentamicin (25 μg/ml).

[0258] HUH7: The human hepatocarcinoma cell line was cultured in DMEM (Sigma)+10% fetal bovine serum (FBS)+2 mM Glutamax I+gentamicin (25 μg/ml)+1× Non Essential Amino Acids.

Example 5

In Vitro Model

Treatment with Antisense Oligonucleotides

[0259] The cells were treated with oligonucleotides using the cationic liposome formulation LipofectAMINE 2000 (Gibco) as transfection vehicle. Cells were seeded in 6-well cell culture plates (NUNC) and treated when 80-90% confluent. Oligomer concentrations ranged from 1 nM to 25 nM final concentration. Formulation of oligomer-lipid complexes was carried out essentially as described by the manufacturer using serum-free OptiMEM (Gibco) and a final lipid concentration of 5 μg/mL LipofectAMINE 2000. Cells were incubated at 37° C. for 4 hours and treatment was stopped by removal of oligomer-containing culture medium. Cells were washed and serum-containing medium was added. After oligomer treatment, cells were allowed to recover for 20 hours before they were harvested for RNA analysis.

Example 6

In Vitro Model

Extraction of RNA and cDNA Synthesis

[0260] Total RNA was extracted from cells transfected as described above and using the Qiagen RNeasy kit (Qiagen cat. no. 74104) according to the manufacturer's instructions. First strand synthesis was performed using Reverse Transcriptase reagents from Ambion according to the manufacturer's instructions.

[0261] For each sample 0.5 μg total RNA was adjusted to (10.8 μl) with RNase free H₂O and mixed with 2 μl random decamers (50 μM) and 4 μl dNTP mix (2.5 mM each dNTP) and heated to 70° C. for 3 min after which the samples were rapidly cooled on ice. After cooling the samples on ice, 2 μl 10× Buffer RT, 1 μl MMLV Reverse Transcriptase (100 U/μl) and 0.25 μl RNase inhibitor (10 U/μl) was added to each sample, followed by incubation at 42° C. for 60 min, heat inactivation of the enzyme at 95° C. for 10 min, and then cooling the sample to 4° C.

Example 7

In Vitro Model

Analysis of Oligonucleotide Inhibition of HER3, EGFR and HER2 Expression by Real-Time PCR

[0262] Antisense modulation of HER3, EGFR and HER2 expression can be assayed in a variety of ways known in the art. For example, HER3, EGFR and HER2 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR. Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or mRNA.

[0263] Methods of RNA isolation and RNA analysis, such as Northern blot analysis, are routine in the art and are taught in, for example, Current Protocols in Molecular Biology, John Wiley and Sons.

[0264] Real-time quantitative (PCR) can be conveniently accomplished using the commercially available Multi-Color Real Time PCR Detection System, available from Applied Biosystem.

Real-Time Quantitative PCR Analysis of HER3, EGFR and HER2 mRNA Levels

[0265] The sample content of human HER3, EGFR and HER2 mRNA was quantified using the human HER3, EGFR and HER2 ABI Prism Pre-Developed TaqMan Assay Reagents (Applied Biosystems cat. no. Hs00951444_m1 (HER3), Hs00193306_m1 (EGFR) and Hs00170433_m1 (HER2) according to the manufacturer's instructions.

[0266] Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA quantity was used as an endogenous control for normalizing any variance in sample preparation. The sample content of human GAPDH mRNA was quantified using the human GAPDH ABI Prism Pre-Developed TaqMan Assay Reagent (Applied Biosystems cat. no. 4310884E) according to the manufacturer's instructions.

[0267] Real-time Quantitative PCR is a technique well known in the art and is taught in for example in Heid et al. Real time quantitative PCR, Genome Research (1996), 6: 986-994.

Real Time PCR

[0268] The cDNA from the first strand synthesis performed as described in Example 5 was diluted 2-20 times, and analyzed by real time quantitative PCR using Taqman 7500 FAST or 7900 FAST from Applied Biosystems. The primers and probe were mixed with 2× Taqman Fast Universal PCR master mix (2×) (Applied Biosystems Cat.#4364103) and added to 4 μl cDNA to a final volume of 10 μl. Each sample was analysed in duplicate. Assaying 2-fold dilutions of a cDNA that had been prepared on material purified from a cell line expressing the RNA of interest generated standard curves for the assays. Sterile H₂O was used instead of cDNA for the no-template control. PCR program: 95° C. for 30 seconds, followed by 40 cycles of 95° C., 3 seconds, 60° C., 20-30 seconds. Relative quantities of target mRNA sequence were determined from the calculated Threshold cycle using the Applied Biosystems Fast System SDS Software Version 1.3.1.21. or SDS Software Version 2.3.

Example 8

In Vitro Analysis

Antisense Inhibition of Human HER3, EGFR and HER2 Expression by Oligonucleotide Compounds

[0269] Oligonucleotides presented in Table 4 were evaluated for their potential to down-regulate HER3, EGFR and HER2 mRNA at concentrations of 1, 5 and 25 nM in 15PC3 cells (or HUH-7 as indicated by *) (see FIGS. 2, 3, 4 and 5). SEQ ID NOs: 235 and 236 were used as scrambled controls.

[0270] The data in Table 4 are presented as percentage down-regulation of mRNA relative to mock transfected cells at 25 nM. Lower-case letters represent DNA monomers, bold, upper-case letters represent β-D-oxy-LNA monomers. All cytosines in LNA monomers are 5-methylcytosines. Subscript "s" represents a phosphorothioate linkage.

TABLE-US-00004 TABLE 4 Inhibition of human HER3, EGFR and HER2 expression by antisense oligonucleotides Test substance Sequence (5'-3') HER3 EGFR HER2 SEQ ID NO: 169 c_{scsasgsascsastscsas} C 93.4% 95.2% 75.8% SEQ ID NO: 170 c_{sasgsascsastscsascs} T 85.8% 91.5% 65.8% SEQ ID NO: 171 a_{scsastscsascstscsts} T 70.6% 84.2% 2.8% SEQ ID NO: 172 c_{sastscsascstscstsgs} G 84.2% 86.2% 61% SEQ ID NO: 173 g_{scstscscsasgsascsas} A 94.5% 96.4% 39.2% SEQ ID NO: 174 c_{sascscsastsasgscsts} A 88.8% 86.4% 94.8% SEQ ID NO: 175 c_{scsasascsascststsgs} C 65.5% 86.1% 76.9% SEQ ID NO: 176 c_{sasascsascststsgsas} A 61.6% 79.4% 74.8% SEQ ID NO: 177 t_{scsastscscsasascsas} T 51.1% 0% 63.4% SEQ ID NO: 178 a_{stscsastscscsasascs} T 76.7% 0% 88.6% SEQ ID NO: 179 g_{stsasgsascsastscsas} T 70.5% 52.6% 75.6% SEQ ID NO: 180 c_{scstsgstscsascststs} C 92.8% N.D. N.D. SEQ ID NO: 181 t_{sgsgscsasasascststs} C 90.6% N.D. N.D. SEQ ID NO: 182 g_{sgscstscsascsascsas} T 74.6% N.D. N.D. SEQ ID NO: 183 t_{scscsasgsgststsgscs} A 85.9% N.D. N.D. SEQ ID NO: 184 t_{scsasasgststscststs} T 81.1% N.D. N.D. SEQ ID NO: 185 t_{sasastststscscststs} G 89.1% N.D. N.D. SEQ ID NO: 186 c_{sasgscsascstsasasts} C 79.9% N.D. N.D. SEQ ID NO: 187 t_{sgscscscstscstsgscs} C 90.4% N.D. N.D. SEQ ID NO: 188 a_{scsascstststsgscscs} C 96.1% N.D. N.D. SEQ ID NO: 189 t_{stscscsasasasgsascs} C 88.9% N.D. N.D. SEQ ID NO: 190 c_{sasastststsgstsascs} C 95.7% N.D. N.D. SEQ ID NO: 191 t_{sgstsgstsastststscs} A 97.7% N.D. N.D. SEQ ID NO: 192 t_{scstsgsastsgsascsts} G 92.3% N.D. N.D. SEQ ID NO: 193 a_{scstscscstscsastscs} C 64% N.D. N.D. SEQ ID NO: 194 c_{scsascsasasasgststs} G 87.5% N.D. N.D. SEQ ID NO: 195 c_{sascstscstsgsgstsgs} T 64.4%* N.D. N.D. SEQ ID NO: 196 a_{stscsascstscstsgsgs} T 77.0%* N.D. N.D. SEQ ID NO: 234 g_{scscstsgstscsas} T SEQ ID NO: 235 c_{sasgstsastsgscsgs} c SEQ ID NO: 236 g_{saststsasgsasas} t SEQ ID NO: 249 c_{scstststsgsascscsts} C

[0271] As shown in Table 4, oligonucleotides having the sequences shown in SEQ ID NOs: 169, 170, 173, 174, 180, 181, 183, 185, 187, 188, 189, 190, 191, 192 and 194 demonstrated about 85% or greater inhibition of HER3 mRNA expression at 25 nM in 15PC3 cells in these experiments, and are therefore preferred.

[0272] Also preferred are oligonucleotides based on the illustrated antisense oligomer sequences, for example varying the length (shorter or longer) and/or monomer content (e.g., the type and/or proportion of nucleoside analogue monomers), which also provide good inhibition of HER3 expression.

Example 9

Apoptosis Induction by LNA Oligonucleotides

[0273] HUH7 cells were seeded in 6-well culture plates (NUNC) the day before transfection at a density of 2.5×10⁵ cells/well. The cells were treated with oligonucleotides using the cationic liposome formulation LipofectAMINE 2000 (Gibco) as transfection vehicle when 75-90% confluent. The oligomer concentrations used were 5 nM and 25 nM (final concentration in well). Formulation of oligomer-lipid complexes was carried out essentially as described by the manufacturer using serum-free OptiMEM (Gibco) and a final lipid concentration of 5 μg/mL LipofectAMINE 2000. Cells were incubated at 37° C. for 4 hours and treatment was stopped by removal of oligomer-containing culture medium. After washing with Optimem, 300 μl of trypsin was added to each well until the cells detached from the wells. The trypsin was inactivated by adding 3 ml HUH7 culture medium to the well and a single cell suspension was made by gently pipetting the cell suspension up and down. The scrambled oligomer SEQ ID NO: 235 was used as control.

[0274] Following this, 100 μl of the cell suspension was added to each well of a white 96-well plate from Nunc (cat #136101) (four plates were prepared, for measurement at different time points). The plates were then incubated at 37° C., 95% humidity and 5% CO₂ until the assays were performed.

Caspase Assay:

[0275] The activities of apoptosis-specific caspases 3 and 7 were measured using a luminogenic Caspase-Glo 3/7-substrate assay (Cat#G8091 from Promega). The plate to be analyzed was equilibrated to room temperature for 15 min. The Caspase-Glo® 3/7 buffer was mixed with the Caspase-Glo® 3/7 substrate to form a Caspase-Glo® working solution which was equilibrated to room temperature. Then, 100 μl of the Caspase-Glo® working solution was carefully added to the medium in each well of the 96-well plate (avoiding bubbles and contamination between wells). The plate was carefully shaken for 1 min, after which it was incubated at room temperature for 1 h, protected from light. The caspase activity was measured as Relative Light Units per second (RLU/s) in a Luminoscan Ascent instrument (Thermo Labsystems). Data were correlated and plotted relative to an average value of the mock samples, which was set to 1. See FIG. 6.

Example 10

In Vitro Inhibition of Proliferation Using LNA Oligonucleotides

[0276] HUH7 cells were transfected and harvested into a single cell suspension as described in Example 9. SEQ ID NO: 235 served as a scrambled control. Following harvesting, 100 μl of the cell suspension was added to each well of a 96-well plate ("Orange Scientific") for MTS assay (four plates were prepared, for measurement at different time points). The plates were then incubated at 37° C., 95% humidity and 5% CO₂ until the assays were performed.

Measurement of Proliferating Viable Cells (MTS Assay)

[0277] For the proliferation assay, 10 μl CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, G3582) were added to the medium of each well of the 96-well plate, the plate was carefully shaken, and incubated at 37° C., 95% humidity and 5% CO₂ for 1 h before measurement. The absorbance was measured at 490 nm in a spectrophotometer and background for the assay was subtracted from wells containing only medium. The absorbance at 490 nm is proportional to the number of viable cells and was plotted over time for the mock transfected cells and for cells transfected with oligomers. See FIG. 7.

Example 11

Evaluation of Target mRNA Knockdown In Vivo

[0278] To evaluate the knockdown efficacy of the HER3 oligomeric compounds in vivo, the female nude mice bearing 15PC3 xenografts developed by subcutaneous injection of 5×10⁶ cells/mouse into the right axillary flank, were injected intravenously with the oligomers at various doses and injection schedules (i.e. single dose, qd, q3d, q4d). Scrambled oligomer SEQ ID NO: 236 served as a negative control. 24 hours after the last injection, the mice were euthanized and liver and tumour tissues were collected in RNAlater solution (Ambion). Total RNA was purified from the tissues and the levels of HER3 mRNA were determined by quantitative reverse transcription-real time PCR (qRT-PCR) using the QuantiTect Probe RT-PCR kit (Cat#: 204443; Qiagen). GAPDH mRNA served as an internal control.

[0279] Mouse HER3: probe: cca cac ctg gtc ata gcg gtg a, primer-1: ctg ttt agg cca agc aga gg, primer-2: att ctg aat cct gcg tcc ac.

[0280] Human HER3: probe: cat tgc cca acc tcc gcg tg, primer-1: tgc agt gga ttc gag aag tg, primer-2: ggc aaa ctt ccc atc gta ga.

[0281] Human GAPDH: probe: act ggc gct gcc aag gct gt, primer-1: cca ccc aga aga ctg tgg at, primer-2: ttc agc tca ggg atg acc tt.

[0282] Mouse GAPDH: probe: agc tgt ggc gtg atg gcc gt, primer-1: aac ttt ggc att gtg gaa gg, primer-2: gga tgc agg gat gat gtt ct 200 ng of total RNA was used in the PCR reaction. The data analyses were performed by using the ABI-7500 PCR Fast System included software. See Table 5.

[0283] Data in Table 5 are presented as % HER3 mRNA levels relative to saline treated controls in liver and tumour samples after i.v. dosing of animals on 5 consecutive days with oligonucleotides in the doses indicated.

TABLE-US-00005 TABLE 5 Inhibition of HER3 mRNA in mouse liver and tumour HER3 mRNA Dosage (mg/kg, i.v., Liver (% of LNA ID qd × 5) Sal ctrl) Tumour (%) SEQ ID 76.3 78 ± 17 100 ± 10.5 NO: 236 60 86.5 ± 9.9 95.5 ± 12.7 30 87.6 ± 19 101.2 ± 21.1 22.9 81.4 ± 6.5 119.3 ± 24.9 SEQ ID 85.3 1 ± 0.3 25.8 ± 4.1 NO: 180 66 6 ± 5.3 32.3 ± 9.7 31.3 1.6 ± 0.3 37 ± 5.8 25.6 3 ± 0.3 .sup. 65 ± 20.2 19.8 1.7 ± 0.6 83.1 ± 19.5 SEQ ID 37.7 20.7 ± 9.8 77 ± 10 NO: 169 11.3 10.2 ± 5.5 ND SEQ ID 32.4 7.4 ± 5.2 78.1 ± 15.3 NO: 172 9.7 12.2 ± 5.9 ND

Example 12

Evaluation of Tumour Growth Inhibition

[0284] The ability of the HER3 specific LNAs to inhibit tumour growth in vivo was evaluated in nude female mice bearing 15PC3 xenografts. 15PC3 human prostate tumour model was developed by subcutaneously injection of 5×10⁶ cells/mouse into the right axillary flank. The tumour volume was determined by measuring two dimensions with callipers and calculated using the formula: tumour volume=(length×width²)/2). When the tumours reached an average volume of 70-100 mm³, the mice bearing tumours were divided into treatment and control groups. The mice were injected intravenously with 25 and 50 mg/kg of SEQ ID NO: 180 respectively, with a q3d×10 schedule. Saline or scrambled oligonucleotide having SEQ ID NO: 236 served as a control. The body weights and tumour sizes of the mice were measured twice weekly. The toxicity was estimated by clinical observation, clinical chemistry and histopathological examination. Tumour HER3 mRNA was measured by QPCR as described in Example 11. See FIGS. 8A and 8B.

Example 13

Inhibition of HER3 mRNA in Mouse Liver

[0285] NMRI mice were dosed i.v. with 1 or 5 mg/kg oligonucleotides on three consecutive days (group size of 5 mice). The antisense oligonucleotides (SEQ ID NO: 180 and SEQ ID NO: 234) were dissolved in 0.9% saline (NaCl). Animals were sacrificed 24 h after last dosing and liver tissue was sampled and stored in RNA later (Ambion) until RNA extraction and QPCR analysis. Total RNA was extracted and HER3 mRNA expression in liver samples was measured by QPCR as described in Example 7 using a mouse HER3QPCR assay (cat. no. Mm01159999_m1, Applied Biosystems). Results were normalised to mouse GAPDH (cat. no. 4352339E, Applied Biosystems) and plotted relative to saline treated controls (see FIG. 9).

Example 14

Preparation of Conjugates of Oligomers with Polyethylene Glycol

[0286] The oligomers having sequences shown as SEQ ID NO: 141 or SEQ ID NO: 152 are functionalized on the 5' terminus by attaching an aminoalkyl group, such as hexan-1-amine blocked with a blocking group such as Fmoc to the 5' phosphate groups of the oligomers using routine phosphoramidite chemistry, oxidizing the resultant compounds, deprotecting them and purifying them to achieve the functionalized oligomers, respectively, having the formulas (IA) and (IB):

##STR00006##

wherein the bold uppercase letters represent nucleoside analogue monomers, lowercase letters represent DNA monomers, and the subscript "s" represents a phosphorothioate linkage.

[0287] A solution of activated PEG, such as the one shown in formula (II):

##STR00007##

wherein the PEG moiety has an average molecular weight of 12,000, and each of the compounds of formulas (IA) and (IB) in PBS buffer are stirred in separate vessels at room temperature for 12 hours. The reaction solutions are extracted three times with methylene chloride and the combined organic layers are dried over magnesium sulphate and filtered and the solvent is evaporated under reduced pressure. The resulting residues are dissolved in double distilled water and loaded onto an anion exchange column. Unreacted PEG linker is eluted with water and the products are eluted with NH₄HCO₃ solution. Fractions containing pure products are pooled and lypophilized to yield the conjugates SEQ ID NOs: 141 and 152, respectively as show in formulas (IIIA) and (IIIB):

##STR00008##

wherein each of the oligomers of SEQ ID NOs: 141 and 152 is attached to a PEG polymer having average molecular weight of 12,000 via a releasable linker. Chemical structures of PEG polymer conjugates that can be made with oligomers having sequences shown in SEQ ID NOs: 169, 180 and 234 using the process described above are respectively shown in formulas (IVA), (IVB) and (IVC):

##STR00009##

wherein bold uppercase letters represent beta-D-oxy-LNA monomers, lowercase letters represent DNA monomers, the subscript "s" represents a phosphorothioate linkage and .sup.MeC represent 5-methylcytosine.

[0288] Activated oligomers that can be used in this process to respectively make the conjugates shown in formulas (IVA), (IVB) and (IVC) have the chemical structures shown in formulas (VA), (VB) and (VC):

##STR00010##

Example 15

Evaluation of Target mRNA Knockdown In Vivo with Different Dosing Cycle

[0289] The knockdown efficacy of oligomers was evaluated in vivo in nude mice bearing xenograft tumours derived from 15PC3 cells or A549 cells (NSCLC) or N87 cells (gastric carcinoma) using a similar protocol to the one described above in

Example 11

[0290] Oligomers were administered by injection every third day in 2-4 doses. Tissues were harvested 3 or 4 days after the last injection.

[0291] Data in Tables 6 and 7 are presented as % HER3 mRNA or HIF-1alpha mRNA relative to saline treated controls in liver and tumour samples after i.v. dosing of animals with the indicated oligomers.

TABLE-US-00006 TABLE 6 Inhibition of ErbB3 mRNA in mouse liver and xenograft tumor derived from 15PC3 cell (3-5 mice/group) Dosage Tumour Liver Treatment (mg/kg) HER3 (%) Hif1A (%) HER3 (%) Saline 0 × 4 100 ± 10 100 ± 8 100 ± 18 SEQ ID 76.3 × 4 106 ± 6.6 101 ± 13.8 115.9 ± 26.3 No: 236 SEQ ID 37.7 × 4 81.6 ± 12.7 94.6 ± 19.6 .sup. 39 ± 4.6 No: 169 SEQ ID 32.4 × 4 107.3 ± 17.sup. 100.3 ± 7.5 44.3 ± 10.6 No: 172 SEQ ID 60.2 × 2 or 3 47.1 ± 2.2 .sup. 101 ± 7.3 6.9 ± 3.6 No: 180 60.2 × 4 54.2 ± 9.1 ND 31.8 ± 5.sup.

[0292] The observed knockdown effects of the oligomers having the sequences of SEQ ID NO: 169 and SEQ ID NO: 180 are not unique to 15PC3 tumour cells, since similar effects were observed in the tumours derived from A549 (NSCLC) and N87 (gastric carcinoma) cells. See Table 7, below.

TABLE-US-00007 TABLE 7 Inhibition of ErbB3 mRNA in mouse liver and xenograft tumor derived from N87 cell (3 mice/group) Xenograft Dosage HER3 (% saline control) model Treatment mg/kg Tumor Liver A549 Saline 0 × 3 100 ± 20.9 100 ± 4.8 SEQ ID 35, q4d × 3 87.6 ± 11.9 97.5 ± 21.2 No: 236 SEQ ID 35, q4d × 3 54.6 ± 15.2 31.8 ± 5.7 No: 180 N87 Saline 0 × 5 100 ± 8.2 100 ± 9.4 SEQ ID 25, q3d × 5 99.0 ± 8.9 123 ± 4.5 No: 249 SEQ ID 25, q3d × 5 46.6 ± 13.4 24.7 ± 3.1 No: 180

SPECIFIC EMBODIMENTS, CITATION OF REFERENCES

[0293] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[0294] Various references, including patent applications, patents, and scientific publications, are cited herein; the disclosure of each such reference is hereby incorporated herein by reference in its entirety.

Sequence CWU 1

248116DNAArtificialAntisense oligonucleotides 1gctccagaca tcactc 16215DNAArtificialAntisense oligonucleotides 2gctccagaca tcact 15315DNAArtificialAntisense oligonucleotides 3ctccagacat cactc 15414DNAArtificialAntisense oligonucleotides 4gctccagaca tcac 14514DNAArtificialAntisense oligonucleotides 5ctccagacat cact 14614DNAArtificialAntisense oligonucleotides 6tccagacatc actc 14713DNAArtificialAntisense oligonucleotides 7gctccagaca tca 13813DNAArtificialAntisense oligonucleotides 8ctccagacat cac 13913DNAArtificialAntisense oligonucleotides 9tccagacatc act 131013DNAArtificialAntisense oligonucleotides 10ccagacatca ctc 131112DNAArtificialAntisense oligonucleotides 11gctccagaca tc 121212DNAArtificialAntisense oligonucleotides 12ctccagacat ca 121312DNAArtificialAntisense oligonucleotides 13tccagacatc ac 121412DNAArtificialAntisense oligonucleotides 14ccagacatca ct 121512DNAArtificialAntisense oligonucleotides 15cagacatcac tc 121616DNAArtificialAntisense oligonucleotides 16ctccagacat cactct 161716DNAArtificialAntisense oligonucleotides 17cagacatcac tctggt 161816DNAArtificialAntisense oligonucleotides 18agacatcact ctggtg 161916DNAArtificialAntisense oligonucleotides 19atagctccag acatca 162015DNAArtificialAntisense oligonucleotides 20atagctccag acatc 152115DNAArtificialAntisense oligonucleotides 21tagctccaga catca 152214DNAArtificialAntisense oligonucleotides 22atagctccag acat 142314DNAArtificialAntisense oligonucleotides 23tagctccaga catc 142414DNAArtificialAntisense oligonucleotides 24agctccagac atca 142513DNAArtificialAntisense oligonucleotides 25atagctccag aca 132613DNAArtificialAntisense oligonucleotides 26tagctccaga cat 132713DNAArtificialAntisense oligonucleotides 27agctccagac atc 132813DNAArtificialAntisense oligonucleotides 28gctccagaca tca 132912DNAArtificialAntisense oligonucleotides 29atagctccag ac 123012DNAArtificialAntisense oligonucleotides 30tagctccaga ca 123112DNAArtificialAntisense oligonucleotides 31agctccagac at 123212DNAArtificialAntisense oligonucleotides 32gctccagaca tc 123312DNAArtificialAntisense oligonucleotides 33ctccagacat ca 123416DNAArtificialAntisense oligonucleotides 34tcacaccata gctcca 163515DNAArtificialAntisense oligonucleotides 35tcacaccata gctcc 153615DNAArtificialAntisense oligonucleotides 36cacaccatag ctcca 153714DNAArtificialAntisense oligonucleotides 37tcacaccata gctc 143814DNAArtificialAntisense oligonucleotides 38cacaccatag ctcc 143914DNAArtificialAntisense oligonucleotides 39acaccatagc tcca 144013DNAArtificialAntisense oligonucleotides 40tcacaccata gct 134113DNAArtificialAntisense oligonucleotides 41cacaccatag ctc 134213DNAArtificialAntisense oligonucleotides 42acaccatagc tcc 134313DNAArtificialAntisense oligonucleotides 43caccatagct cca 134412DNAArtificialAntisense oligonucleotides 44tcacaccata gc 124512DNAArtificialAntisense oligonucleotides 45cacaccatag ct 124612DNAArtificialAntisense oligonucleotides 46acaccatagc tc 124712DNAArtificialAntisense oligonucleotides 47caccatagct cc 124812DNAArtificialAntisense oligonucleotides 48accatagctc ca 124916DNAArtificialAntisense oligonucleotides 49catccaacac ttgacc 165016DNAArtificialAntisense oligonucleotides 50atccaacact tgacca 165116DNAArtificialAntisense oligonucleotides 51caatcatcca acactt 165216DNAArtificialAntisense oligonucleotides 52tcaatcatcc aacact 165316DNAArtificialAntisense oligonucleotides 53catgtagaca tcaatt 165416DNAArtificialAntisense oligonucleotides 54tagcctgtca cttctc 165516DNAArtificialAntisense oligonucleotides 55agatggcaaa cttccc 165616DNAArtificialAntisense oligonucleotides 56caaggctcac acatct 165716DNAArtificialAntisense oligonucleotides 57aagtccaggt tgccca 165816DNAArtificialAntisense oligonucleotides 58cattcaagtt cttcat 165916DNAArtificialAntisense oligonucleotides 59cactaatttc cttcag 166015DNAArtificialAntisense oligonucleotides 60cactaatttc cttca 156115DNAArtificialAntisense oligonucleotides 61actaatttcc ttcag 156214DNAArtificialAntisense oligonucleotides 62cactaatttc cttc 146314DNAArtificialAntisense oligonucleotides 63actaatttcc ttca 146414DNAArtificialAntisense oligonucleotides 64ctaatttcct tcag 146513DNAArtificialAntisense oligonucleotides 65cactaatttc ctt 136613DNAArtificialAntisense oligonucleotides 66actaatttcc ttc 136713DNAArtificialAntisense oligonucleotides 67ctaatttcct tca 136813DNAArtificialAntisense oligonucleotides 68taatttcctt cag 136912DNAArtificialAntisense oligonucleotides 69cactaatttc ct 127012DNAArtificialAntisense oligonucleotides 70actaatttcc tt 127112DNAArtificialAntisense oligonucleotides 71ctaatttcct tc 127212DNAArtificialAntisense oligonucleotides 72taatttcctt ca 127312DNAArtificialAntisense oligonucleotides 73aatttccttc ag 127416DNAArtificialAntisense oligonucleotides 74gcccagcact aatttc 167516DNAArtificialAntisense oligonucleotides 75ctttgccctc tgccac 167616DNAArtificialAntisense oligonucleotides 76cacacacttt gccctc 167715DNAArtificialAntisense oligonucleotides 77cacacacttt gccct 157815DNAArtificialAntisense oligonucleotides 78acacactttg ccctc 157914DNAArtificialAntisense oligonucleotides 79cacacacttt gccc 148014DNAArtificialAntisense oligonucleotides 80acacactttg ccct 148114DNAArtificialAntisense oligonucleotides 81cacactttgc cctc 148213DNAArtificialAntisense oligonucleotides 82cacacacttt gcc 138313DNAArtificialAntisense oligonucleotides 83acacactttg ccc 138413DNAArtificialAntisense oligonucleotides 84cacactttgc cct 138513DNAArtificialAntisense oligonucleotides 85acactttgcc ctc 138612DNAArtificialAntisense oligonucleotides 86cacacacttt gc 128712DNAArtificialAntisense oligonucleotides 87acacactttg cc 128812DNAArtificialAntisense oligonucleotides 88cacactttgc cc 128912DNAArtificialAntisense oligonucleotides 89acactttgcc ct 129012DNAArtificialAntisense oligonucleotides 90cactttgccc tc 129116DNAArtificialAntisense oligonucleotides 91cagttccaaa gacacc 169216DNAArtificialAntisense oligonucleotides 92tggcaatttg tactcc 169315DNAArtificialAntisense oligonucleotides 93tggcaatttg tactc 159415DNAArtificialAntisense oligonucleotides 94ggcaatttgt actcc 159514DNAArtificialAntisense oligonucleotides 95tggcaatttg tact 149614DNAArtificialAntisense oligonucleotides 96ggcaatttgt actc 149714DNAArtificialAntisense oligonucleotides 97gcaatttgta ctcc 149813DNAArtificialAntisense oligonucleotides 98tggcaatttg tac 139913DNAArtificialAntisense oligonucleotides 99ggcaatttgt act 1310013DNAArtificialAntisense oligonucleotides 100gcaatttgta ctc 1310113DNAArtificialAntisense oligonucleotides 101caatttgtac tcc 1310212DNAArtificialAntisense oligonucleotides 102tggcaatttg ta 1210312DNAArtificialAntisense oligonucleotides 103ggcaatttgt ac 1210412DNAArtificialAntisense oligonucleotides 104gcaatttgta ct 1210512DNAArtificialAntisense oligonucleotides 105caatttgtac tc 1210612DNAArtificialAntisense oligonucleotides 106aatttgtact cc 1210716DNAArtificialAntisense oligonucleotides 107gtgtgtgtat ttccca 1610815DNAArtificialAntisense oligonucleotides 108gtgtgtgtat ttccc 1510915DNAArtificialAntisense oligonucleotides 109tgtgtgtatt tccca 1511014DNAArtificialAntisense oligonucleotides 110gtgtgtgtat ttcc 1411114DNAArtificialAntisense oligonucleotides 111tgtgtgtatt tccc 1411214DNAArtificialAntisense oligonucleotides 112gtgtgtattt ccca 1411313DNAArtificialAntisense oligonucleotides 113gtgtgtgtat ttc 1311413DNAArtificialAntisense oligonucleotides 114tgtgtgtatt tcc 1311513DNAArtificialAntisense oligonucleotides 115gtgtgtattt ccc 1311613DNAArtificialAntisense oligonucleotides 116tgtgtatttc cca 1311712DNAArtificialAntisense oligonucleotides 117gtgtgtgtat tt 1211812DNAArtificialAntisense oligonucleotides 118tgtgtgtatt tc 1211912DNAArtificialAntisense oligonucleotides 119gtgtgtattt cc 1212012DNAArtificialAntisense oligonucleotides 120tgtgtatttc cc 1212112DNAArtificialAntisense oligonucleotides 121gtgtatttcc ca 1212216DNAArtificialAntisense oligonucleotides 122ccctctgatg actctg 1612315DNAArtificialAntisense oligonucleotides 123ccctctgatg actct 1512415DNAArtificialAntisense oligonucleotides 124cctctgatga ctctg 1512514DNAArtificialAntisense oligonucleotides 125ccctctgatg actc 1412614DNAArtificialAntisense oligonucleotides 126cctctgatga ctct 1412714DNAArtificialAntisense oligonucleotides 127ctctgatgac tctg 1412813DNAArtificialAntisense oligonucleotides 128ccctctgatg act 1312913DNAArtificialAntisense oligonucleotides 129cctctgatga ctc 1313013DNAArtificialAntisense oligonucleotides 130ctctgatgac tct 1313113DNAArtificialAntisense oligonucleotides 131tctgatgact ctg 1313212DNAArtificialAntisense oligonucleotides 132ccctctgatg ac 1213312DNAArtificialAntisense oligonucleotides 133cctctgatga ct 1213412DNAArtificialAntisense oligonucleotides 134ctctgatgac tc 1213512DNAArtificialAntisense oligonucleotides 135tctgatgact ct 1213612DNAArtificialAntisense oligonucleotides 136ctgatgactc tg 1213716DNAArtificialAntisense oligonucleotides 137catactcctc atcttc 1613816DNAArtificialAntisense oligonucleotides 138ccaccacaaa gttatg 1613916DNAArtificialAntisense oligonucleotides 139catcactctg gtgtgt 1614016DNAArtificialAntisense oligonucleotides 140gacatcactc tggtgt 1614116DNAArtificialOligonucleotide designs 141gctccagaca tcactc 1614216DNAArtificialOligonucleotide designs 142ctccagacat cactct

1614316DNAArtificialOligonucleotide designs 143cagacatcac tctggt 1614416DNAArtificialOligonucleotide designs 144agacatcact ctggtg 1614516DNAArtificialOligonucleotide designs 145atagctccag acatca 1614616DNAArtificialOligonucleotide designs 146tcacaccata gctcca 1614716DNAArtificialOligonucleotide designs 147catccaacac ttgacc 1614816DNAArtificialOligonucleotide designs 148atccaacact tgacca 1614916DNAArtificialOligonucleotide designs 149caatcatcca acactt 1615016DNAArtificialOligonucleotide designs 150tcaatcatcc aacact 1615116DNAArtificialOligonucleotide designs 151catgtagaca tcaatt 1615216DNAArtificialOligonucleotide designs 152tagcctgtca cttctc 1615316DNAArtificialOligonucleotide designs 153agatggcaaa cttccc 1615416DNAArtificialOligonucleotide designs 154caaggctcac acatct 1615516DNAArtificialOligonucleotide designs 155aagtccaggt tgccca 1615616DNAArtificialOligonucleotide designs 156cattcaagtt cttcat 1615716DNAArtificialOligonucleotide designs 157cactaatttc cttcag 1615816DNAArtificialOligonucleotide designs 158gcccagcact aatttc 1615916DNAArtificialOligonucleotide designs 159ctttgccctc tgccac 1616016DNAArtificialOligonucleotide designs 160cacacacttt gccctc 1616116DNAArtificialOligonucleotide designs 161cagttccaaa gacacc 1616216DNAArtificialOligonucleotide designs 162tggcaatttg tactcc 1616316DNAArtificialOligonucleotide designs 163gtgtgtgtat ttccca 1616416DNAArtificialOligonucleotide designs 164ccctctgatg actctg 1616516DNAArtificialOligonucleotide designs 165catactcctc atcttc 1616616DNAArtificialOligonucleotide designs 166ccaccacaaa gttatg 1616716DNAArtificialOligonucleotide designs 167catcactctg gtgtgt 1616816DNAArtificialOligonucleotide designs 168gacatcactc tggtgt 1616916DNAArtificialLNA oligomers 169gctccagaca tcactc 1617016DNAArtificialLNA oligomers 170ctccagacat cactct 1617116DNAArtificialLNA oligomers 171cagacatcac tctggt 1617216DNAArtificialLNA oligomers 172agacatcact ctggtg 1617316DNAArtificialLNA oligomers 173atagctccag acatca 1617416DNAArtificialLNA oligomers 174tcacaccata gctcca 1617516DNAArtificialLNA oligomers 175catccaacac ttgacc 1617616DNAArtificialLNA oligomers 176atccaacact tgacca 1617716DNAArtificialLNA oligomers 177caatcatcca acactt 1617816DNAArtificialLNA oligomers 178tcaatcatcc aacact 1617916DNAArtificialLNA oligomers 179catgtagaca tcaatt 1618016DNAArtificialLNA oligomers 180tagcctgtca cttctc 1618116DNAArtificialLNA oligomers 181agatggcaaa cttccc 1618216DNAArtificialLNA oligomers 182caaggctcac acatct 1618316DNAArtificialLNA oligomers 183aagtccaggt tgccca 1618416DNAArtificialLNA oligomers 184cattcaagtt cttcat 1618516DNAArtificialLNA oligomers 185cactaatttc cttcag 1618616DNAArtificialLNA oligomers 186gcccagcact aatttc 1618716DNAArtificialLNA oligomers 187ctttgccctc tgccac 1618816DNAArtificialLNA oligomers 188cacacacttt gccctc 1618916DNAArtificialLNA oligomers 189cagttccaaa gacacc 1619016DNAArtificialLNA oligomers 190tggcaatttg tactcc 1619116DNAArtificialLNA oligomers 191gtgtgtgtat ttccca 1619216DNAArtificialLNA oligomers 192ccctctgatg actctg 1619316DNAArtificialLNA oligomers 193catactcctc atcttc 1619416DNAArtificialLNA oligomers 194ccaccacaaa gttatg 1619516DNAArtificialLNA oligomers 195catcactctg gtgtgt 1619616DNAArtificialLNA oligomers 196gacatcactc tggtgt 161975511DNAhomo sapiens 197acacacacac acccctcccc tgccatccct ccccggactc cggctccggc tccgattgca 60atttgcaacc tccgctgccg tcgccgcagc agccaccaat tcgccagcgg ttcaggtggc 120tcttgcctcg atgtcctagc ctaggggccc ccgggccgga cttggctggg ctcccttcac 180cctctgcgga gtcatgaggg cgaacgacgc tctgcaggtg ctgggcttgc ttttcagcct 240ggcccggggc tccgaggtgg gcaactctca ggcagtgtgt cctgggactc tgaatggcct 300gagtgtgacc ggcgatgctg agaaccaata ccagacactg tacaagctct acgagaggtg 360tgaggtggtg atggggaacc ttgagattgt gctcacggga cacaatgccg acctctcctt 420cctgcagtgg attcgagaag tgacaggcta tgtcctcgtg gccatgaatg aattctctac 480tctaccattg cccaacctcc gcgtggtgcg agggacccag gtctacgatg ggaagtttgc 540catcttcgtc atgttgaact ataacaccaa ctccagccac gctctgcgcc agctccgctt 600gactcagctc accgagattc tgtcaggggg tgtttatatt gagaagaacg ataagctttg 660tcacatggac acaattgact ggagggacat cgtgagggac cgagatgctg agatagtggt 720gaaggacaat ggcagaagct gtcccccctg tcatgaggtt tgcaaggggc gatgctgggg 780tcctggatca gaagactgcc agacattgac caagaccatc tgtgctcctc agtgtaatgg 840tcactgcttt gggcccaacc ccaaccagtg ctgccatgat gagtgtgccg ggggctgctc 900aggccctcag gacacagact gctttgcctg ccggcacttc aatgacagtg gagcctgtgt 960acctcgctgt ccacagcctc ttgtctacaa caagctaact ttccagctgg aacccaatcc 1020ccacaccaag tatcagtatg gaggagtttg tgtagccagc tgtccccata actttgtggt 1080ggatcaaaca tcctgtgtca gggcctgtcc tcctgacaag atggaagtag ataaaaatgg 1140gctcaagatg tgtgagcctt gtgggggact atgtcccaaa gcctgtgagg gaacaggctc 1200tgggagccgc ttccagactg tggactcgag caacattgat ggatttgtga actgcaccaa 1260gatcctgggc aacctggact ttctgatcac cggcctcaat ggagacccct ggcacaagat 1320ccctgccctg gacccagaga agctcaatgt cttccggaca gtacgggaga tcacaggtta 1380cctgaacatc cagtcctggc cgccccacat gcacaacttc agtgtttttt ccaatttgac 1440aaccattgga ggcagaagcc tctacaaccg gggcttctca ttgttgatca tgaagaactt 1500gaatgtcaca tctctgggct tccgatccct gaaggaaatt agtgctgggc gtatctatat 1560aagtgccaat aggcagctct gctaccacca ctctttgaac tggaccaagg tgcttcgggg 1620gcctacggaa gagcgactag acatcaagca taatcggccg cgcagagact gcgtggcaga 1680gggcaaagtg tgtgacccac tgtgctcctc tgggggatgc tggggcccag gccctggtca 1740gtgcttgtcc tgtcgaaatt atagccgagg aggtgtctgt gtgacccact gcaactttct 1800gaatggggag cctcgagaat ttgcccatga ggccgaatgc ttctcctgcc acccggaatg 1860ccaacccatg gagggcactg ccacatgcaa tggctcgggc tctgatactt gtgctcaatg 1920tgcccatttt cgagatgggc cccactgtgt gagcagctgc ccccatggag tcctaggtgc 1980caagggccca atctacaagt acccagatgt tcagaatgaa tgtcggccct gccatgagaa 2040ctgcacccag gggtgtaaag gaccagagct tcaagactgt ttaggacaaa cactggtgct 2100gatcggcaaa acccatctga caatggcttt gacagtgata gcaggattgg tagtgatttt 2160catgatgctg ggcggcactt ttctctactg gcgtgggcgc cggattcaga ataaaagggc 2220tatgaggcga tacttggaac ggggtgagag catagagcct ctggacccca gtgagaaggc 2280taacaaagtc ttggccagaa tcttcaaaga gacagagcta aggaagctta aagtgcttgg 2340ctcgggtgtc tttggaactg tgcacaaagg agtgtggatc cctgagggtg aatcaatcaa 2400gattccagtc tgcattaaag tcattgagga caagagtgga cggcagagtt ttcaagctgt 2460gacagatcat atgctggcca ttggcagcct ggaccatgcc cacattgtaa ggctgctggg 2520actatgccca gggtcatctc tgcagcttgt cactcaatat ttgcctctgg gttctctgct 2580ggatcatgtg agacaacacc ggggggcact ggggccacag ctgctgctca actggggagt 2640acaaattgcc aagggaatgt actaccttga ggaacatggt atggtgcata gaaacctggc 2700tgcccgaaac gtgctactca agtcacccag tcaggttcag gtggcagatt ttggtgtggc 2760tgacctgctg cctcctgatg ataagcagct gctatacagt gaggccaaga ctccaattaa 2820gtggatggcc cttgagagta tccactttgg gaaatacaca caccagagtg atgtctggag 2880ctatggtgtg acagtttggg agttgatgac cttcggggca gagccctatg cagggctacg 2940attggctgaa gtaccagacc tgctagagaa gggggagcgg ttggcacagc cccagatctg 3000cacaattgat gtctacatgg tgatggtcaa gtgttggatg attgatgaga acattcgccc 3060aacctttaaa gaactagcca atgagttcac caggatggcc cgagacccac cacggtatct 3120ggtcataaag agagagagtg ggcctggaat agcccctggg ccagagcccc atggtctgac 3180aaacaagaag ctagaggaag tagagctgga gccagaacta gacctagacc tagacttgga 3240agcagaggag gacaacctgg caaccaccac actgggctcc gccctcagcc taccagttgg 3300aacacttaat cggccacgtg ggagccagag ccttttaagt ccatcatctg gatacatgcc 3360catgaaccag ggtaatcttg gggagtcttg ccaggagtct gcagtttctg ggagcagtga 3420acggtgcccc cgtccagtct ctctacaccc aatgccacgg ggatgcctgg catcagagtc 3480atcagagggg catgtaacag gctctgaggc tgagctccag gagaaagtgt caatgtgtag 3540gagccggagc aggagccgga gcccacggcc acgcggagat agcgcctacc attcccagcg 3600ccacagtctg ctgactcctg ttaccccact ctccccaccc gggttagagg aagaggatgt 3660caacggttat gtcatgccag atacacacct caaaggtact ccctcctccc gggaaggcac 3720cctttcttca gtgggtctca gttctgtcct gggtactgaa gaagaagatg aagatgagga 3780gtatgaatac atgaaccgga ggagaaggca cagtccacct catcccccta ggccaagttc 3840ccttgaggag ctgggttatg agtacatgga tgtggggtca gacctcagtg cctctctggg 3900cagcacacag agttgcccac tccaccctgt acccatcatg cccactgcag gcacaactcc 3960agatgaagac tatgaatata tgaatcggca acgagatgga ggtggtcctg ggggtgatta 4020tgcagccatg ggggcctgcc cagcatctga gcaagggtat gaagagatga gagcttttca 4080ggggcctgga catcaggccc cccatgtcca ttatgcccgc ctaaaaactc tacgtagctt 4140agaggctaca gactctgcct ttgataaccc tgattactgg catagcaggc ttttccccaa 4200ggctaatgcc cagagaacgt aactcctgct ccctgtggca ctcagggagc atttaatggc 4260agctagtgcc tttagagggt accgtcttct ccctattccc tctctctccc aggtcccagc 4320cccttttccc cagtcccaga caattccatt caatctttgg aggcttttaa acattttgac 4380acaaaattct tatggtatgt agccagctgt gcactttctt ctctttccca accccaggaa 4440aggttttcct tattttgtgt gctttcccag tcccattcct cagcttcttc acaggcactc 4500ctggagatat gaaggattac tctccatatc ccttcctctc aggctcttga ctacttggaa 4560ctaggctctt atgtgtgcct ttgtttccca tcagactgtc aagaagagga aagggaggaa 4620acctagcaga ggaaagtgta attttggttt atgactctta accccctaga aagacagaag 4680cttaaaatct gtgaagaaag aggttaggag tagatattga ttactatcat aattcagcac 4740ttaactatga gccaggcatc atactaaact tcacctacat tatctcactt agtcctttat 4800catccttaaa acaattctgt gacatacata ttatctcatt ttacacaaag ggaagtcggg 4860catggtggct catgcctgta atctcagcac tttgggaggc tgaggcagaa ggattacctg 4920aggcaaggag tttgagacca gcttagccaa catagtaaga cccccatctc tttaaaaaaa 4980aaaaaaaaaa aaaaaaaaaa actttagaac tgggtgcagt ggctcatgcc tgtaatccca 5040gccagcactt tgggaggctg agatgggaag atcacttgag cccagaatta gagataagcc 5100tatggaaaca tagcaagaca ctgtctctac aggggaaaaa aaaaaaagaa actgagcctt 5160aaagagatga aataaattaa gcagtagatc caggatgcaa aatcctccca attcctgtgc 5220atgtgctctt attgtaaggt gccaagaaaa actgatttaa gttacagccc ttgtttaagg 5280ggcactgttt cttgtttttg cactgaatca agtctaaccc caacagccac atcctcctat 5340acctagacat ctcatctcag gaagtggtgg tgggggtagt cagaaggaaa aataactgga 5400catctttgtg taaaccataa tccacatgtg ccgtaaatga tcttcactcc ttatccgagg 5460gcaaattcac aaggatcccc aagatccact tttagaagcc attctcatcc a 55111985616DNAhomo sapiens 198ccccggcgca gcgcggccgc agcagcctcc gccccccgca cggtgtgagc gcccgacgcg 60gccgaggcgg ccggagtccc gagctagccc cggcggccgc cgccgcccag accggacgac 120aggccacctc gtcggcgtcc gcccgagtcc ccgcctcgcc gccaacgcca caaccaccgc 180gcacggcccc ctgactccgt ccagtattga tcgggagagc cggagcgagc tcttcgggga 240gcagcgatgc gaccctccgg gacggccggg gcagcgctcc tggcgctgct ggctgcgctc 300tgcccggcga gtcgggctct ggaggaaaag aaagtttgcc aaggcacgag taacaagctc 360acgcagttgg gcacttttga agatcatttt ctcagcctcc agaggatgtt caataactgt 420gaggtggtcc ttgggaattt ggaaattacc tatgtgcaga ggaattatga tctttccttc 480ttaaagacca tccaggaggt ggctggttat gtcctcattg ccctcaacac agtggagcga 540attcctttgg aaaacctgca gatcatcaga ggaaatatgt actacgaaaa ttcctatgcc 600ttagcagtct tatctaacta tgatgcaaat aaaaccggac tgaaggagct gcccatgaga 660aatttacagg aaatcctgca tggcgccgtg cggttcagca acaaccctgc cctgtgcaac 720gtggagagca tccagtggcg ggacatagtc agcagtgact ttctcagcaa catgtcgatg 780gacttccaga accacctggg cagctgccaa aagtgtgatc caagctgtcc caatgggagc 840tgctggggtg caggagagga gaactgccag aaactgacca aaatcatctg tgcccagcag 900tgctccgggc gctgccgtgg caagtccccc agtgactgct gccacaacca gtgtgctgca 960ggctgcacag gcccccggga gagcgactgc ctggtctgcc gcaaattccg agacgaagcc 1020acgtgcaagg acacctgccc cccactcatg ctctacaacc ccaccacgta ccagatggat 1080gtgaaccccg agggcaaata cagctttggt gccacctgcg tgaagaagtg tccccgtaat 1140tatgtggtga cagatcacgg ctcgtgcgtc cgagcctgtg gggccgacag ctatgagatg 1200gaggaagacg gcgtccgcaa gtgtaagaag tgcgaagggc cttgccgcaa agtgtgtaac 1260ggaataggta ttggtgaatt taaagactca ctctccataa atgctacgaa tattaaacac 1320ttcaaaaact gcacctccat cagtggcgat ctccacatcc tgccggtggc atttaggggt 1380gactccttca cacatactcc tcctctggat ccacaggaac tggatattct gaaaaccgta 1440aaggaaatca cagggttttt gctgattcag gcttggcctg aaaacaggac ggacctccat 1500gcctttgaga acctagaaat catacgcggc aggaccaagc aacatggtca gttttctctt 1560gcagtcgtca gcctgaacat aacatccttg ggattacgct ccctcaagga gataagtgat 1620ggagatgtga taatttcagg aaacaaaaat ttgtgctatg caaatacaat aaactggaaa 1680aaactgtttg ggacctccgg tcagaaaacc aaaattataa gcaacagagg tgaaaacagc 1740tgcaaggcca caggccaggt ctgccatgcc ttgtgctccc ccgagggctg ctggggcccg 1800gagcccaggg actgcgtctc ttgccggaat gtcagccgag gcagggaatg cgtggacaag 1860tgcaaccttc tggagggtga gccaagggag tttgtggaga actctgagtg catacagtgc 1920cacccagagt gcctgcctca ggccatgaac atcacctgca caggacgggg accagacaac 1980tgtatccagt gtgcccacta cattgacggc ccccactgcg tcaagacctg cccggcagga 2040gtcatgggag aaaacaacac cctggtctgg aagtacgcag acgccggcca tgtgtgccac 2100ctgtgccatc caaactgcac ctacggatgc actgggccag gtcttgaagg ctgtccaacg 2160aatgggccta agatcccgtc catcgccact gggatggtgg gggccctcct cttgctgctg 2220gtggtggccc tggggatcgg cctcttcatg cgaaggcgcc acatcgttcg gaagcgcacg 2280ctgcggaggc tgctgcagga gagggagctt gtggagcctc ttacacccag tggagaagct 2340cccaaccaag ctctcttgag gatcttgaag gaaactgaat tcaaaaagat caaagtgctg 2400ggctccggtg cgttcggcac ggtgtataag ggactctgga tcccagaagg tgagaaagtt 2460aaaattcccg tcgctatcaa ggaattaaga gaagcaacat ctccgaaagc caacaaggaa 2520atcctcgatg aagcctacgt gatggccagc gtggacaacc cccacgtgtg ccgcctgctg 2580ggcatctgcc tcacctccac cgtgcagctc atcacgcagc tcatgccctt cggctgcctc 2640ctggactatg tccgggaaca caaagacaat attggctccc agtacctgct caactggtgt 2700gtgcagatcg caaagggcat gaactacttg gaggaccgtc gcttggtgca ccgcgacctg 2760gcagccagga acgtactggt gaaaacaccg cagcatgtca agatcacaga ttttgggctg 2820gccaaactgc tgggtgcgga agagaaagaa taccatgcag aaggaggcaa agtgcctatc 2880aagtggatgg cattggaatc aattttacac agaatctata cccaccagag tgatgtctgg 2940agctacgggg tgaccgtttg ggagttgatg acctttggat ccaagccata tgacggaatc 3000cctgccagcg agatctcctc catcctggag aaaggagaac gcctccctca gccacccata 3060tgtaccatcg atgtctacat gatcatggtc aagtgctgga tgatagacgc agatagtcgc 3120ccaaagttcc gtgagttgat catcgaattc tccaaaatgg cccgagaccc ccagcgctac 3180cttgtcattc agggggatga aagaatgcat ttgccaagtc ctacagactc caacttctac 3240cgtgccctga tggatgaaga agacatggac gacgtggtgg atgccgacga gtacctcatc 3300ccacagcagg gcttcttcag cagcccctcc acgtcacgga ctcccctcct gagctctctg 3360agtgcaacca gcaacaattc caccgtggct tgcattgata gaaatgggct gcaaagctgt 3420cccatcaagg aagacagctt cttgcagcga tacagctcag accccacagg cgccttgact 3480gaggacagca tagacgacac cttcctccca gtgcctgaat acataaacca gtccgttccc 3540aaaaggcccg ctggctctgt gcagaatcct gtctatcaca atcagcctct gaaccccgcg 3600cccagcagag acccacacta ccaggacccc cacagcactg cagtgggcaa ccccgagtat 3660ctcaacactg tccagcccac ctgtgtcaac agcacattcg acagccctgc ccactgggcc 3720cagaaaggca gccaccaaat tagcctggac aaccctgact accagcagga cttctttccc 3780aaggaagcca agccaaatgg catctttaag ggctccacag ctgaaaatgc agaataccta 3840agggtcgcgc cacaaagcag tgaatttatt ggagcatgac

cacggaggat agtatgagcc 3900ctaaaaatcc agactctttc gatacccagg accaagccac agcaggtcct ccatcccaac 3960agccatgccc gcattagctc ttagacccac agactggttt tgcaacgttt acaccgacta 4020gccaggaagt acttccacct cgggcacatt ttgggaagtt gcattccttt gtcttcaaac 4080tgtgaagcat ttacagaaac gcatccagca agaatattgt ccctttgagc agaaatttat 4140ctttcaaaga ggtatatttg aaaaaaaaaa aaagtatatg tgaggatttt tattgattgg 4200ggatcttgga gtttttcatt gtcgctattg atttttactt caatgggctc ttccaacaag 4260gaagaagctt gctggtagca cttgctaccc tgagttcatc caggcccaac tgtgagcaag 4320gagcacaagc cacaagtctt ccagaggatg cttgattcca gtggttctgc ttcaaggctt 4380ccactgcaaa acactaaaga tccaagaagg ccttcatggc cccagcaggc cggatcggta 4440ctgtatcaag tcatggcagg tacagtagga taagccactc tgtcccttcc tgggcaaaga 4500agaaacggag gggatggaat tcttccttag acttactttt gtaaaaatgt ccccacggta 4560cttactcccc actgatggac cagtggtttc cagtcatgag cgttagactg acttgtttgt 4620cttccattcc attgttttga aactcagtat gctgcccctg tcttgctgtc atgaaatcag 4680caagagagga tgacacatca aataataact cggattccag cccacattgg attcatcagc 4740atttggacca atagcccaca gctgagaatg tggaatacct aaggatagca ccgcttttgt 4800tctcgcaaaa acgtatctcc taatttgagg ctcagatgaa atgcatcagg tcctttgggg 4860catagatcag aagactacaa aaatgaagct gctctgaaat ctcctttagc catcacccca 4920accccccaaa attagtttgt gttacttatg gaagatagtt ttctcctttt acttcacttc 4980aaaagctttt tactcaaaga gtatatgttc cctccaggtc agctgccccc aaaccccctc 5040cttacgcttt gtcacacaaa aagtgtctct gccttgagtc atctattcaa gcacttacag 5100ctctggccac aacagggcat tttacaggtg cgaatgacag tagcattatg agtagtgtgg 5160aattcaggta gtaaatatga aactagggtt tgaaattgat aatgctttca caacatttgc 5220agatgtttta gaaggaaaaa agttccttcc taaaataatt tctctacaat tggaagattg 5280gaagattcag ctagttagga gcccaccttt tttcctaatc tgtgtgtgcc ctgtaacctg 5340actggttaac agcagtcctt tgtaaacagt gttttaaact ctcctagtca atatccaccc 5400catccaattt atcaaggaag aaatggttca gaaaatattt tcagcctaca gttatgttca 5460gtcacacaca catacaaaat gttccttttg cttttaaagt aatttttgac tcccagatca 5520gtcagagccc ctacagcatt gttaagaaag tatttgattt ttgtctcaat gaaaataaaa 5580ctatattcat ttccactcta aaaaaaaaaa aaaaaa 56161994624DNAhomo sapiens 199ggaggaggtg gaggaggagg gctgcttgag gaagtataag aatgaagttg tgaagctgag 60attcccctcc attgggaccg gagaaaccag gggagccccc cgggcagccg cgcgcccctt 120cccacggggc cctttactgc gccgcgcgcc cggcccccac ccctcgcagc accccgcgcc 180ccgcgccctc ccagccgggt ccagccggag ccatggggcc ggagccgcag tgagcaccat 240ggagctggcg gccttgtgcc gctgggggct cctcctcgcc ctcttgcccc ccggagccgc 300gagcacccaa gtgtgcaccg gcacagacat gaagctgcgg ctccctgcca gtcccgagac 360ccacctggac atgctccgcc acctctacca gggctgccag gtggtgcagg gaaacctgga 420actcacctac ctgcccacca atgccagcct gtccttcctg caggatatcc aggaggtgca 480gggctacgtg ctcatcgctc acaaccaagt gaggcaggtc ccactgcaga ggctgcggat 540tgtgcgaggc acccagctct ttgaggacaa ctatgccctg gccgtgctag acaatggaga 600cccgctgaac aataccaccc ctgtcacagg ggcctcccca ggaggcctgc gggagctgca 660gcttcgaagc ctcacagaga tcttgaaagg aggggtcttg atccagcgga acccccagct 720ctgctaccag gacacgattt tgtggaagga catcttccac aagaacaacc agctggctct 780cacactgata gacaccaacc gctctcgggc ctgccacccc tgttctccga tgtgtaaggg 840ctcccgctgc tggggagaga gttctgagga ttgtcagagc ctgacgcgca ctgtctgtgc 900cggtggctgt gcccgctgca aggggccact gcccactgac tgctgccatg agcagtgtgc 960tgccggctgc acgggcccca agcactctga ctgcctggcc tgcctccact tcaaccacag 1020tggcatctgt gagctgcact gcccagccct ggtcacctac aacacagaca cgtttgagtc 1080catgcccaat cccgagggcc ggtatacatt cggcgccagc tgtgtgactg cctgtcccta 1140caactacctt tctacggacg tgggatcctg caccctcgtc tgccccctgc acaaccaaga 1200ggtgacagca gaggatggaa cacagcggtg tgagaagtgc agcaagccct gtgcccgagt 1260gtgctatggt ctgggcatgg agcacttgcg agaggtgagg gcagttacca gtgccaatat 1320ccaggagttt gctggctgca agaagatctt tgggagcctg gcatttctgc cggagagctt 1380tgatggggac ccagcctcca acactgcccc gctccagcca gagcagctcc aagtgtttga 1440gactctggaa gagatcacag gttacctata catctcagca tggccggaca gcctgcctga 1500cctcagcgtc ttccagaacc tgcaagtaat ccggggacga attctgcaca atggcgccta 1560ctcgctgacc ctgcaagggc tgggcatcag ctggctgggg ctgcgctcac tgagggaact 1620gggcagtgga ctggccctca tccaccataa cacccacctc tgcttcgtgc acacggtgcc 1680ctgggaccag ctctttcgga acccgcacca agctctgctc cacactgcca accggccaga 1740ggacgagtgt gtgggcgagg gcctggcctg ccaccagctg tgcgcccgag ggcactgctg 1800gggtccaggg cccacccagt gtgtcaactg cagccagttc cttcggggcc aggagtgcgt 1860ggaggaatgc cgagtactgc aggggctccc cagggagtat gtgaatgcca ggcactgttt 1920gccgtgccac cctgagtgtc agccccagaa tggctcagtg acctgttttg gaccggaggc 1980tgaccagtgt gtggcctgtg cccactataa ggaccctccc ttctgcgtgg cccgctgccc 2040cagcggtgtg aaacctgacc tctcctacat gcccatctgg aagtttccag atgaggaggg 2100cgcatgccag ccttgcccca tcaactgcac ccactcctgt gtggacctgg atgacaaggg 2160ctgccccgcc gagcagagag ccagccctct gacgtccatc atctctgcgg tggttggcat 2220tctgctggtc gtggtcttgg gggtggtctt tgggatcctc atcaagcgac ggcagcagaa 2280gatccggaag tacacgatgc ggagactgct gcaggaaacg gagctggtgg agccgctgac 2340acctagcgga gcgatgccca accaggcgca gatgcggatc ctgaaagaga cggagctgag 2400gaaggtgaag gtgcttggat ctggcgcttt tggcacagtc tacaagggca tctggatccc 2460tgatggggag aatgtgaaaa ttccagtggc catcaaagtg ttgagggaaa acacatcccc 2520caaagccaac aaagaaatct tagacgaagc atacgtgatg gctggtgtgg gctccccata 2580tgtctcccgc cttctgggca tctgcctgac atccacggtg cagctggtga cacagcttat 2640gccctatggc tgcctcttag accatgtccg ggaaaaccgc ggacgcctgg gctcccagga 2700cctgctgaac tggtgtatgc agattgccaa ggggatgagc tacctggagg atgtgcggct 2760cgtacacagg gacttggccg ctcggaacgt gctggtcaag agtcccaacc atgtcaaaat 2820tacagacttc gggctggctc ggctgctgga cattgacgag acagagtacc atgcagatgg 2880gggcaaggtg cccatcaagt ggatggcgct ggagtccatt ctccgccggc ggttcaccca 2940ccagagtgat gtgtggagtt atggtgtgac tgtgtgggag ctgatgactt ttggggccaa 3000accttacgat gggatcccag cccgggagat ccctgacctg ctggaaaagg gggagcggct 3060gccccagccc cccatctgca ccattgatgt ctacatgatc atggtcaaat gttggatgat 3120tgactctgaa tgtcggccaa gattccggga gttggtgtct gaattctccc gcatggccag 3180ggacccccag cgctttgtgg tcatccagaa tgaggacttg ggcccagcca gtcccttgga 3240cagcaccttc taccgctcac tgctggagga cgatgacatg ggggacctgg tggatgctga 3300ggagtatctg gtaccccagc agggcttctt ctgtccagac cctgccccgg gcgctggggg 3360catggtccac cacaggcacc gcagctcatc taccaggagt ggcggtgggg acctgacact 3420agggctggag ccctctgaag aggaggcccc caggtctcca ctggcaccct ccgaaggggc 3480tggctccgat gtatttgatg gtgacctggg aatgggggca gccaaggggc tgcaaagcct 3540ccccacacat gaccccagcc ctctacagcg gtacagtgag gaccccacag tacccctgcc 3600ctctgagact gatggctacg ttgcccccct gacctgcagc ccccagcctg aatatgtgaa 3660ccagccagat gttcggcccc agcccccttc gccccgagag ggccctctgc ctgctgcccg 3720acctgctggt gccactctgg aaaggcccaa gactctctcc ccagggaaga atggggtcgt 3780caaagacgtt tttgcctttg ggggtgccgt ggagaacccc gagtacttga caccccaggg 3840aggagctgcc cctcagcccc accctcctcc tgccttcagc ccagccttcg acaacctcta 3900ttactgggac caggacccac cagagcgggg ggctccaccc agcaccttca aagggacacc 3960tacggcagag aacccagagt acctgggtct ggacgtgcca gtgtgaacca gaaggccaag 4020tccgcagaag ccctgatgtg tcctcaggga gcagggaagg cctgacttct gctggcatca 4080agaggtggga gggccctccg accacttcca ggggaacctg ccatgccagg aacctgtcct 4140aaggaacctt ccttcctgct tgagttccca gatggctgga aggggtccag cctcgttgga 4200agaggaacag cactggggag tctttgtgga ttctgaggcc ctgcccaatg agactctagg 4260gtccagtgga tgccacagcc cagcttggcc ctttccttcc agatcctggg tactgaaagc 4320cttagggaag ctggcctgag aggggaagcg gccctaaggg agtgtctaag aacaaaagcg 4380acccattcag agactgtccc tgaaacctag tactgccccc catgaggaag gaacagcaat 4440ggtgtcagta tccaggcttt gtacagagtg cttttctgtt tagtttttac tttttttgtt 4500ttgttttttt aaagatgaaa taaagaccca gggggagaat gggtgttgta tggggaggca 4560agtgtggggg gtccttctcc acacccactt tgtccatttg caaatatatt ttggaaaaca 4620gcta 462420024DNAArtificial24mers Sequence motif 200catagctcca gacatcactc tggt 2420124DNAArtificial24mers Sequence motif 201atagctccag acatcactct ggtg 2420224DNAArtificial24mers Sequence motif 202gctccagaca tcactctggt gtgt 2420324DNAArtificial24mers Sequence motif 203ctccagacat cactctggtg tgtg 2420424DNAArtificial24mers Sequence motif 204caccatagct ccagacatca ctct 2420524DNAArtificial24mers Sequence motif 205actgtcacac catagctcca gaca 2420624DNAArtificial24mers Sequence motif 206caatcatcca acacttgacc atca 2420724DNAArtificial24mers Sequence motif 207aatcatccaa cacttgacca tcac 2420824DNAArtificial24mers Sequence motif 208tcatcaatca tccaacactt gacc 2420924DNAArtificial24mers Sequence motif 209ctcatcaatc atccaacact tgac 2421024DNAArtificial24mers Sequence motif 210tcaccatgta gacatcaatt gtgc 2421124DNAArtificial24mers Sequence motif 211gacatagcct gtcacttctc gaat 2421224DNAArtificial24mers Sequence motif 212acgaagatgg caaacttccc atcg 2421324DNAArtificial24mers Sequence motif 213cccacaaggc tcacacatct tgag 2421424DNAArtificial24mers Sequence motif 214cagaaagtcc aggttgccca ggat 2421524DNAArtificial24mers Sequence motif 215gtgacattca agttcttcat gatc 2421624DNAArtificial24mers Sequence motif 216ccagcactaa tttccttcag ggat 2421724DNAArtificial24mers Sequence motif 217atacgcccag cactaatttc cttc 2421824DNAArtificial24mers Sequence motif 218cacactttgc cctctgccac gcag 2421924DNAArtificial24mers Sequence motif 219gggtcacaca ctttgccctc tgcc 2422024DNAArtificial24mers Sequence motif 220tgcacagttc caaagacacc cgag 2422124DNAArtificial24mers Sequence motif 221cccttggcaa tttgtactcc ccag 2422224DNAArtificial24mers Sequence motif 222tctggtgtgt gtatttccca aagt 2422324DNAArtificial24mers Sequence motif 223atgcccctct gatgactctg atgc 2422424DNAArtificial24mers Sequence motif 224tattcatact cctcatcttc atct 2422524DNAArtificial24mers Sequence motif 225tgatccacca caaagttatg ggga 2422624DNAArtificial24mers Sequence motif 226cagacatcac tctggtgtgt gtat 2422724DNAArtificial24mers Sequence motif 227tccagacatc actctggtgt gtgt 2422815DNAArtificialAntisense oligonucleotides 228tagcctgtca cttct 1522915DNAArtificialAntisense oligonucleotides 229agcctgtcac ttctc 1523014DNAArtificialAntisense oligonucleotides 230tagcctgtca cttc 1423114DNAArtificialAntisense oligonucleotides 231agcctgtcac ttct 1423213DNAArtificialAntisense oligonucleotides 232tagcctgtca ctt 1323312DNAArtificialAntisense oligonucleotides 233tagcctgtca ct 1223413DNAArtificialLNA oligomers 234tagcctgtca ctt 1323516DNAArtificialLNA oligomers 235cgtcagtatg cgaatc 1623616DNAArtificialLNA oligomers 236cgcagattag aaacct 1623722DNAArtificialprobe sequence 237ccacacctgg tcatagcggt ga 2223820DNAArtificialprobe sequence 238ctgtttaggc caagcagagg 2023920DNAArtificialprobe sequence 239attctgaatc ctgcgtccac 2024020DNAArtificialprobe sequence 240cattgcccaa cctccgcgtg 2024120DNAArtificialprobe sequence 241tgcagtggat tcgagaagtg 2024220DNAArtificialprobe sequence 242ggcaaacttc ccatcgtaga 2024320DNAArtificialprobe sequence 243actggcgctg ccaaggctgt 2024420DNAArtificialprobe sequence 244ccacccagaa gactgtggat 2024520DNAArtificialprobe sequence 245ttcagctcag ggatgacctt 2024620DNAArtificialprobe sequence 246agctgtggcg tgatggccgt 2024720DNAArtificialprobe sequence 247aactttggca ttgtggaagg 2024820DNAArtificialprobe sequence 248ggatgcaggg atgatgttct 20

Claims

1-30. (canceled)

31. An oligomer selected from the group consisting of: TABLE-US-00008 (SEQ ID NO: 169) 5'-G_s.sup.MeC_sT_{scscsasgsascs}- a_stscsas.sup.MeC_sT_s.sup.MeC-3', (SEQ ID NO: 172) 5'-A_sG_sA_{scsastscsascsts}- c_stsgsG_sT_sG-3', (SEQ ID NO: 173) 5'-A_sT_sA_{sgscstscscsasgs}- a_scsasT_s.sup.MeC_sA-3', and (SEQ ID NO: 174) 5'-T_s.sup.MeC_sA_{scsascscsasts}- a_sgscsts.sup.MeC_s.sup.MeC_sA-3',

wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and .sup.MeC denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.

32. The oligomer according to claim 1, which inhibits the expression of a human HER3 gene or mRNA in a cell that expresses HER3.

33. A pharmaceutical composition comprising the oligomer according to claim 1, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

34. A conjugate comprising an oligomer according to claim 1 covalently attached to at least one moiety that is not a nucleic acid or a monomer.

35. A pharmaceutical composition comprising the conjugate according to claim 34, and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

36. A method of inhibiting the expression of HER3 in a cell, comprising contacting said cell with an oligomer selected from the group consisting of: TABLE-US-00009 (SEQ ID NO: 169) 5'-G_s.sup.MeC_sT_{scscsasgsascs}- a_stscsas.sup.MeC_sT_s.sup.MeC-3', (SEQ ID NO: 172) 5'-A_sG_sA_{scsastscsascsts}- c_stsgsG_sT_sG-3', (SEQ ID NO: 173) 5'-A_sT_sA_{sgscstscscsasgs}- a_scsasT_s.sup.MeC_sA-3', and (SEQ ID NO: 174) 5'-T_s.sup.MeC_sA_{scsascscsasts}- a_sgscsts.sup.MeC_s.sup.MeC_sA-3',

wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and .sup.MeC denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.

37. A method of inhibiting the expression of HER3 in a cell, comprising contacting said cell with an effective amount of a conjugate according to claim 34.

38. A method of inhibiting the expression of HER3 in a tissue of a mammal, comprising contacting said tissue with an effective amount of an oligomer selected from the group consisting of: TABLE-US-00010 (SEQ ID NO: 169) 5'-G_s.sup.MeC_sT_{scscsasgsascs}- a_stscsas.sup.MeC_sT_s.sup.MeC-3', (SEQ ID NO: 172) 5'-A_sG_sA_{scsastscsascsts}- c_stsgsG_sT_sG-3', (SEQ ID NO: 173) 5'-A_sT_sA_{sgscstscscsasgs}- a_scsasT_s.sup.MeC_sA-3', and (SEQ ID NO: 174) 5'-T_s.sup.MeC_sA_{scsascscsasts}- a_sgscsts.sup.MeC_s.sup.MeC_sA-3',

wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and .sup.MeC denotes a beta-D-oxy-LNA monomer containing a 5-methylcytosine base.

39. A method of inhibiting the expression of HER3 in a tissue of a mammal comprising contacting said tissue with an effective amount of a conjugate according to claim 34.

40. A method of treating cancer in a mammal, comprising administering to said mammal an effective amount of an oligomer selected from the group consisting of: TABLE-US-00011 (SEQ ID NO: 169) 5'-G_s.sup.MeC_sT_{scscsasgsascs}- a_stscsas.sup.MeC_sT_s.sup.MeC-3', (SEQ ID NO: 172) 5'-A_sG_sA_{scsastscsascsts}- c_stsgsG_sT_sG-3', (SEQ ID NO: 173) 5'-A_sT_sA_{sgscstscscsasgs}- a_scsasT_s.sup.MeC_sA-3', and (SEQ ID NO: 174) 5'-T_s.sup.MeC_sA_{scsascscsasts}- a_sgscsts.sup.MeC_s.sup.MeC_sA-3',

wherein uppercase letters denote beta-D-oxy-LNA monomers and lowercase letters denote DNA monomers, the subscript "s" denotes a phosphorothioate linkage, and .sup.MeC denotes a beta-D-oxyLNA monomer containing a 5-methylcytosine base.

41. The method of claim 40, wherein the cancer is selected from non-Hodgkin's lymphoma, Hodgkin's lymphoma, acute leukemia such as acute lymphocytic leukemia, acute myelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, colon carcinoma, rectal carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, cervical cancer, testicular cancer, lung carcinoma, bladder carcinoma, melanoma, head and neck cancer, brain cancer, cancers of unknown primary site, neoplasms, cancers of the peripheral nervous system, cancers of the central nervous system, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumour, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogcnic carcinoma, seminoma, embryonal carcinoma, Wilms' tumour, small cell lung carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pincaloma, hemamio blastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, and retinoblastoma

Images